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ABSTRACT
Antimicrobial resistance has become an alarming public health concern since early
2000’s. Infections caused by multidrug resistant bacteria not only increase the mortality
rate but also increase the economic burden globally. One approach to alleviate this issue is
to find novel drug targets. In this regard, the bacterial lysine biosynthesis pathway provides
several targets that may be used for design of antimicrobial compounds. Bacteria use lysine
or meso-diaminopimelate to crosslink the peptidoglycan monomers in the bacterial cell
wall. As such, we hypothesize that blocking this pathway will induce defects in the
bacterial cell wall that are similar to those caused by β-lactam antibiotics. This study is
directed towards identifying the potential of 4-hydroxy-tetrahydrodipicolinate reductase
(DapB), an enzyme from lysine biosynthesis pathway as a drug target. DapB is a tetrameric
enzyme that catalyzes NAD(P)H dependent reduction of (2S, 4S)-4-hydroxy-2,3,4,5tetrahydrodipicolinate to generate 2,3,4,5-tetrahydrodipicolinate. This research uses
biophysical and biochemical techniques to study the structures of these enzymes and
identify potential inhibitory compounds. Interactions of DapB with cofactors and potential
inhibitors are described. Major emphasis is placed on studies of DapB from Neisseria
gonorrhoeae. Additionally, DapB enzymes from Mycobacterium tuberculosis and Vibrio
vulnificus are also discussed.
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CHAPTER 1
4- HYDROXY-TETRAHYDRODIPICOLINATE REDUCTASE AS A
NOVEL DRUG TARGET IN PATHOGENIC BACTERIA

1.1. ANTIBIOTIC RESISTANCE IN PATHOGENIC BACTERIA
The advances in health care and use of antimicrobials for eradication of pathogens
has greatly helped in increasing life expectancy over last few decades 1. A major challenge
that is affecting the efficacy of these antimicrobials is development of antibiotic resistance
by pathogenic bacteria. Unrestricted use of antibiotics, over prescribing existing antibiotics
and lack of new drugs are some of the main reasons that are leading to exponential increase
in drug resistant pathogens. Use of antibiotics as growth supplements in livestock to
promote health and improve yield and quality of livestock products has also attributed to
spread of drug resistant bacteria, which is aggravating the antibiotic resistance crisis 2.
Infections caused by multidrug resistant bacteria not only increase the mortality rate 2-3 but
also increase the economic burden by several billion dollars in the United States 4. Owing
to these persistent repercussions, multi drug resistant pathogens are identified as severe
public health hazard by the Centers for Disease Control and Prevention (CDC) and World
Health Organization. CDC annually publishes a list of drug resistant pathogens that pose
immediate threat to human health (Table 1.1) 5. The first step to combat this issue is to
gather more insights with regards to how pathogens become resistant to antibiotics.

1

Studies on the dynamics of antibiotic- pathogen interactions at the molecular level show
that the majority of antibiotics target cell wall synthesis, protein synthesis, as well as DNA
replication and repair in bacteria

6

. Enzymes containing trans peptidase and

transglycosylase domains, ribosomal machinery, and DNA gyrase act as site of actions for
antibiotics within these specific pathways 7. Unfortunately, pathogenic bacteria have
developed many molecular and biochemical defensive mechanisms to evade the
antibiotics. Most common genetic strategies used by bacteria are mutations in
chromosomal genes and horizontal gene transfer (HGT) 8. Emergence of antibiotic
resistance in hospital environments has been attributed to HGT 9. Biochemical strategies
include chemical alteration or degradation of the antibiotic by enzymes 10, modification of
the site at which the antibiotic acts 11 and finding ways to bypass antibiotic targets. Another
common strategy is to decrease the permeability of bacterial cell wall to antibiotics and
development of efflux pumps 9.
Researchers have identified several approaches that can give solutions for the
problem of antibiotic resistance. The most direct approaches involve development of new
classes for antibiotics and compounds that disrupt drug resistance mechanisms 7. Studies
have also diversified from the existing drug targets and several new bacterial components
have gained attention due to their potential as novel drug targets. These include bacterial
proteases

12

, two component signal transduction systems

13

, riboswitches

14

and several

enzymes involved in central metabolic pathways 15. Disrupting enzymes involved in central
biosynthetic pathways will greatly reduce the survival and pathogenicity of bacteria due to
lack of alternative biosynthetic cycles. Fatty acid synthesis 16, vitamin biosynthesis 17, ATP

2

synthesis 18 and amino acid biosynthesis 19 are some of the pathways that are being studied
as drug targets.
1.2. LYSINE BIOSYNTHESIS PATHWAY AS A NOVEL DRUG TARGET
Lysine is an essential amino acid in mammals but is produced by all bacteria, fungi
and plants. The complete absence of enzymes involved in lysine biosynthesis in mammals,
suggests that the compounds inhibiting lysine biosynthesis may have novel antibacterial
activity with low mammalian toxicity thus making this pathway an ideal candidate for
evaluation as drug target

20

. The initial step of lysine production involves conversion of

aspartate to aspartyl phosphate by the enzyme aspartate kinase (Figure 1.1). Aspartate
semialdehyde dehydrogenase (ASADH) then catalyzes reductive dephosphorylation of
aspartyl phosphate to form aspartate semialdehyde (ASA) using NADP+ as a cofactor.
These steps also initiate de novo synthesis of other amino acids like threonine, isoleucine
and methionine. The first committed step for lysine biosynthesis is catalyzed by an amine
lyase, 4-hydroxy-tetrahydrodipicolinate synthase (DapA). This enzyme synthesizes
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate from aspartate semialdehyde and
pyruvate. The next step is catalyzed by 4-hydroxy-tetrahydrodipicolinate reductase (DapB)
and results in formation of 2,3,4,5-tetrahydrodipicolinate. After this point several
variations are seen in different organisms all of which result into formation of the same
product; meso-diaminopimelate (meso-Dap). These variations include succinylase,
dehydrogenase, aminotransferase and acetylase pathways

21

. The last step is

decarboxylation of meso-Dap to form lysine catalyzed by Dap decarboxylase. The
succinylase pathway depicted in Figure 1, is used to form meso-Dap by majority of
bacterial species 20.

3

The last two products of the pathway; meso-Dap and lysine, are important for
maintaining the integrity of a microbial cell. Microorganisms use these compounds to
covalently link peptidoglycan in the cell wall 22. Hence, blocking the production of these
compounds will introduce defects in cell wall synthesis and protein production due to
lysine deficiency 20. Apart from role in cell wall synthesis and protein synthesis, lysine is
the central catalytic residue for activity of several bacterial enzymes 23-25. Lysine also plays
role in pathogenicity of some bacteria like Pseudomonas syringae and helps bacteria to
survive at low pH 26. Therefore, blocking lysine biosynthesis is detrimental to bacteria.
ASADH, DapA and DapB can be good drug targets especially for development of
broad spectrum antibiotics, due to their essentiality and omnipresence across microbial
species. The following paragraphs describe the general structure and the current research
on inhibitors for these enzymes.
1.3. ASPARTATE SEMIALDEHYDE DEHYDROGENASE (ASADH)
Research on ASADH as a potential drug target has been gaining attention for over
two decades. The unique position of the enzyme in biosynthesis of several amino acids, its
essentiality for viability of bacteria 27, and its role in virulence of pathogens like Salmonella
enterica

28

and Yersinia pestis

29

has motivated scientists to look for inhibitors for this

enzyme. Structurally, all bacterial ASADH’s are homodimers

30

. Each monomer has N-

terminal cofactor binding domain and C-terminal dimerization domain. The
oligomerization state of the enzyme is vital for its activity since the enzyme exhibits half
site reactivity with respect to its substrate

31

. The enzyme forms ASA using mechanism

characteristic to the glyceraldehyde 3- phosphate family and requires a catalytic cysteine
(Cys135, E. coli ASADH numbering) for its activity 30.

4

Diverse approaches have been employed to search and design inhibitors of this
enzyme. These include probing the active site 32 and intermediates in the enzyme reaction
33

as well as using computational based approaches like fragment screening

molecular docking

35-36

34

and

along with structure based design for inhibitors. The natural

inhibitor for this enzyme is the amino acid cystine (and its derivatives). L-cystine is the
most potent inhibitor in this class followed closely by D-cysteine, L-cysteine dimethyl ester
and L- cysteine diethyl ester. These compounds block the enzyme activity by binding to
the active site cysteine 32. Inhibitors based on reaction intermediates include compounds
like oxyanion periodate

37

, whereas substrate analogs studies using molecular docking

include methylene phosphonate, difluoromethylene phosphonate, phosphoramidate
analogues, Z-olefin, acetylene and monofluorophosphate

35, 38

. Another study based on

fragment screening method emphasized on the inhibitory potential of L and D-cysteine.
Additional inhibitors like 5-aminocaproate, D-glutamate, 3-nitropropionate, trans-3hexenedioic acid, 2-aminobutyrate and 4-hydroxybenzophenone were also identified in
this study 34.
1.4. 4-HYDROXY-TETRAHYDRODIPICOLINATE SYNTHASE (DapA)
DapA catalyzes the first committed step in lysine biosynthesis production

20

.

Therefore, this enzyme is a good target for development of inhibitors. The active site of
the enzyme is located at the C- terminal end of the TIM barrel domain and consists of
highly conserved lysine residue and a catalytic triad formed by two tyrosine and one
threonine residue (Lys161 , Tyr133 and Tyr107, Thr44 - numbered according to E. coli
DapA) 39. The enzyme follows a ping pong mechanism and uses two substrates namely,
ASA and pyruvate. The reaction starts with binding of pyruvate to the active lysine and

5

then proceeds via formation of enamine intermediate which undergoes condensation with
ASA to release the product 40. Crystal structure studies on this enzyme indicate that DapA
is a tetrameric enzyme

41

. The tetramer is said to be a dimer of dimers. The tight dimer

interface helps to form the active site of the two monomers and the allosteric binding site
of lysine 42.
From the point of view of inhibitor development, different research groups have
identified pyruvate analogues that inhibit the enzyme. 3-fluoropyruvate, α-ketobutyrate, αketovalerate, glyoxylate 43 and α, ε-diketopimelic acid 44 show competitive inhibition with
respect to pyruvate whereas α-ketopimelic acid has been reported to be an irreversible
inhibitor of DapA

45

. Turner et al.

46

studied compounds that mimic the intermediate

product formed in the enzyme reaction and identified diethyl (E,E)-4-oxo-2,5heptadienedioate and diethyl (E)-4-oxo-2-heptenedioate as irreversible inhibitors

46

. In

another study, DapA inhibitors were generated based on a series of piperidine and 2,6pyridinedicarboxylic acid (2,6-PDC) derivatives that resemble its product. 2,6-PDC was
found to have a Ki of 18 mM with respect to ASA and 11 mM with respect to pyruvate. In
the same study, a number of other analogues were synthesized but showed poor inhibition
46-47

.

1.5. 4-HYDROXY-TETRAHYDRODIPICOLINATE REDUCTASE
4-hydroxy-tetrahydrodipicolinate

reductase

(DapB)

formerly

known

as

dihydrodipicolinate reductase catalyzes the reduction of (2S,4S)-4-hydroxy-2,3,4,5tetrahydrodipicolinate to 2,3,4,5-tetrahydrodipicolinate in an NADH/NADPH dependent
reaction (Figure 1.1). DapB is shown to be essential gene in several bacteria including
Bacillus subtilis, Haemophilus influenza, Helicobacter pylori, Acinetobacter baylyi,

6

Pseudomonas aeruginosa, Salmonella enterica serovar Typhi, Escherichia coli,
Porphyromonas gingivalis, Burkholderia thailandensis, Mycobacterium tuberculosis,
Shewanella oneidensis, etc. 48.
Structurally, all the bacterial homologs of DapB enzyme exhibit homotetrameric
biological assembly (Figure 1.4A). Each monomer can be segregated into two distinct
domains namely cofactor/coenzyme binding (consisting majorly residues from the Nterminus) and the oligomerization domain (C-terminus) 49. The cofactor binding domain
adopts the Rossmann fold: a super secondary structure composed of alternative α-helices
and β-strands 50. This domain binds to nucleotide via a GXXGXXG motif that is conserved
in most of the known DapB’s 51. The oligomerization domain is not only responsible for
the biological assembly but also has the substrate binding site. This domain is also
composed of α-helices and β-strands. The β-strands from each monomer interact with each
other to form a central β-barrel that forms the base for the tetrameric assembly (Figure
1.4B). The oligomerization domain consists of a conserved EXHHXXKXDXPSGTX
motif that include substrate binding residues and the central active site lysine residue.
Another feature observed in DapB’s that drives the enzyme reaction is the change
in conformation upon ligand binding. Binding of cofactor induces a change primarily in
nucleotide binding domain resulting into partial closure of each monomer. This change is
usually less than 10°. However, binding of both the cofactor and substrate/substrate analogs
induces a major conformational change (>30°) resulting into complete closure of the
monomer (Figure 1.5) 52.

7

1.6. SEQUENCE SIMILARITY BETWEEN DapB HOMOLOGS
One notable feature that makes DapB’s attractive drug targets is the sequence
identity shared by various homologs. Table 1.2 and Figure 1.3 depict the sequence identity
between DapB homologs that have their structure determined and deposited in PDB. This
relatively high sequence identity of DapB’s across both Gram positive and Gram negative
bacteria highlights the potential of compounds inhibiting these enzymes as broad spectrum
antibiotics. Based on the structure, all bacterial DapB’s are homotetratmers. As described
above, each monomer in these enzymes is composed of cofactor binding domain
(consisting majorly residues from the N-terminus) and the oligomerization domain (most
of the C-terminal part of the protein chain).
In an extensive computational study, full length sequences of DapB homologs,
corresponding to proteins from Pfam families 4-hydroxy-tetrahydrodipicolinate reductase
N-terminus (DapB_N - PF01113; cofactor binding domain) and 4-hydroxytetrahydrodipicolinate reductase C-terminus (DapB_C - PF05173; oligomerization
domain), were analyzed 53. A dataset of 4907 sequences was formed from the sequences in
the Pfam database. Sequence similarities between subgroups of related proteins was
visualized using CLANS (CLuster ANalysis of Sequences)

54

, where the P-values of

highly-scoring segment pairs (HSPs) obtained from an N × N BLAST search, were used
to compute attractive and repulsive forces between each sequence pair. Force is an
algorithm that divides the most similar points (attractive forces) and point sharing least
similarity (repulsive forces) amongst the sequences in separate clusters 55. The clustering
was performed in 2D, using P-value threshold of 1e-6.

8

The analysis revealed that the domain organization, where both cofactor binding
and oligomerization domains are present is the most common architecture among DapB
homologs (Figure 1.2). There are four clusters of protein sequences annotated as DapB.
The largest cluster, 4-hydroxy-tetrahydrodipicolinate reductase I comprises mostly DapB’s
from Proteobacteria, including structurally characterized DapB’s from Bartonella
henselae, Burkholderia thailandensis, Escherichia coli, Pseudomonas aeruginosa,
Staphylococcus aureus, Neisseria gonorrhoeae, Vibrio vulnificus and Thermotoga
maritima. Second group of DapB’s (cluster 4-hydroxy-tetrahydrodipicolinate reductase II)
is predominantly composed of proteins from bacteria belonging to phylum bacteroidetes
and has no structurally characterized representatives. Sequences in this cluster show high
similarity to 4-hydroxy-tetrahydrodipicolinate reductase cluster I, but not III. The third
group (cluster 4-hydroxy-tetrahydrodipicolinate reductase III) is divided into two
subgroups, one comprising proteins from Actinobacteria represented by structurally
characterized

proteins

from

Corynebacterium

glutamicum

and

Mycobacterium

tuberculosis. The second subgroup comprises of protein sequences of bacteria from
phylum Firmicutes and Cyanobacteria. Additionally, it also has proteins from Viridiplantae
chloroplasts. In contrast to the three groups mentioned above, that have both domains,
proteins in the fourth cluster 4-hydroxy-tetrahydrodipicolinate reductase IV) have only
well-defined N-terminal DapB_N domain and unclassified C-terminal extension. These
proteins show similarity to clusters I and II, and only second subgroup of cluster III 56.
Two of the groups showing the lowest similarity to DapB’s formed two satellite
clusters. One comprising of poorly characterized proteins with N-terminal DapB_N
domain and C-terminal SAF domain. Second, composed of multi-domain proteins,

9

annotated as various transcription regulators, characterized by the presence of DapB_N
domain accompanied by several domains including Per-Arnt-Sim (PAS) domains,
responsible for binding of various proteins and small molecules, a regulatory Sigma-54
interaction domain, and helix-turn-helix motif.
Another distantly related cluster (Glyceraldehyde-3-phosphate dehydrogenases) is
represented by proteins characterized by the presence of DapB_N domain (PF01113)
merged to glyceraldehyde 3-phosphate dehydrogenase C-terminal domain (PF02800). This
group shows closest similarity to cluster of meso-Dap D-dehydrogenases, where the
DapB_N domain are accompanied by diaminopimelic acid dehydrogenase C-terminal
domains (PF16654).
1.7.

INHIBITORS

OF

4-HYDROXY-TETRAHYDRODIPICOLINATE

REDUCTASE
During enzyme reaction, the active site of DapB is occupied by the substrate and
co factor NAD(P)H. Enzymatic characterization of DapB enzyme is challenging due to the
unstable nature of its substrate. Therefore, DapB is often characterized enzymatically using
a dual enzyme assay coupled with DapA, which uses ASA and pyruvate as substrates. The
formation of DapB substrate is quantified based on ASA concentrations in the dual enzyme
assay 57. In terms of inhibition by substrate concentration, DapB homologs exhibit variable
behavior. High substrate concentrations were found to inhibit TmDapB and SaDapB 49, 58.
On the other hand, high substrate concentrations showed no inhibition for EcDapB,
MtDapB and PaDapB using the dual enzyme assay

52

. Another approach was to screen

substrate analogs for inhibitory potential. In this regard, 2,6-pyridine dicarboxylic acid
(2,6-PDC) is the only known inhibitor. This compound is a competitive inhibitor of

10

EcDapB with a Ki of 55 µM 59. In one of the studies aimed at DapB inhibitor development,
molecular modeling was used to design inhibitors for MtDapB. A novel benzyl
sulfonamide based scaffold was used to design and synthesize different compounds. All
the compounds (Table 1.4, compounds A to E) were found to be competitive inhibitors
with respect to the substrate. The structures and Ki values for these compounds are listed
in Table 1.4. The same group also used conventional high throughput screening and
identified four novel compounds (Table 1.4, compounds F to I). These compounds showed
micromolar Ki values, but were not as promising as the benzyl sulfonamide inhibitors
identified by molecular modeling (Table 1.4) 60. In another study, compounds mimicking
the cofactor-substrate complex were tested as inhibitors (Table 1.4, compound J)

61

.

However, no research describing further studies on these compounds is available.
The descriptions above clearly indicate that there are many studies identifying the
potential of ASADH and DapA as drug targets. Several potential inhibitory compounds
have already been identified for these two enzymes 32-35, 39-40. However, reports on DapB
as potential drug target are limited. The following chapters focus on studying the potential
of DapB enzyme as a drug target along with studies identifying potential inhibitors for the
enzyme. Major emphasis is on studies of DapB from Neisseria gonorrhoeae (NgDapB).
DapB enzymes from Mycobacterium tuberculosis (MtDapB) and Vibrio vulnificus
(VvDapB) are also discussed.
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1.8. TABLES
Table 1.1: Antibiotic resistant pathogens 62
Urgent Threats

Serious Threats

•

Clostridioides difficile

•

Acinetobacter

•

Enterobacteriaceae

•

Campylobacter

(Carbapenem resistant )

•

Candida (Fluconazole

•

Neisseria gonorrhoeae

Concerning Threats
•

(Vancomycin resistant )
•

ESBL producing
Enterobacteriaceae

•

Salmonella

•

Shigella

•

MRSA

•

Streptococcus pneumonia

•

Mycobacterium
tuberculosis
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Group A Streptococcus
(Erythromycin resistant)

resistant )
•

Staphylococcus aureus

•

Group B Streptococcus
(Clindamycin resistant)

Table 1.2: Structures of Bacterial DapB’s in PDB. Structures deposited in PDB and
described in following chapters are marked in bold.
Organism

PDB ID

Gram Negative Bacteria
Anabaena variabilis (cyanobacteria) 5KT0
Burkholderia thailandensis

4F3Y

Bartonella henselae

3IJP

Coxiella burnetii

5WOL

Escherichia coli

1ARZ, 1DIH, 1DRU, 1DRV, 1DRW

Neisseria gonorrhoeae

6BDX

Neisseria meningitidis

5UGJ

Pseudomonas aeruginosa

4YWJ

Thermatoga maritima

1VM6

Vibrio vulnificus

5TEJ, 5TEM, 5TEN, 5US6

Gram Positive Bacteria
Corynebacterium glutamicum

5EER, 5EES

Staphylococcus aureus

3QY9

Paenisporosarcina sp. TG-14

5Z2E, 5Z2F, 5Z2D

Other Bacteria
Mycobacterium tuberculosis

5TEK, 5TJY, 5TJZ, 5UGV,
1C3V, 1P9L, 1YL5, 1YL6, 1YL7
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Table 1.3: Sequence identity matrix for DapB’s with structures in PDB. DapB with 10-30 %, 31-60 % and 61-100 % identity are
shown in white blue and green respectively. [AvDapB: Anabaena variabilis, BtDapB; Burkholderia thailandensis, BhDapB; Bartonella
henselae, CbDapB; Coxiella burnetti, EcDapB; Escherichia coli, NgDapB; Neisseria gonorrhoeae, NmDapB; Neisseria meningitidis,
PsDapB; Pseudomonas aeruginosa, TmDapB; Thermotoga maritima, VvDapB; Vibrio vulnificus, CgDapB; Corynebacterium
glutanicum, SaDapB; Staphylococcus aureus, PaDapB; Paenisporosarcina sp. TG-14, MtDapB; Mycobacterium tuberculosis]
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AvDapB
BtDapB
BhDapB
CbDapB
EcDapB
NgDapB
NmDapB
PsDapB
TmDapB
VvDapB

Av
DapB
100
27.2
26.9
46.8
26.4
26.8
26.8
30.4
29.0
27.8

Bt
DapB

Bh
DapB

Cb
DapB

100
40.7
32.1
57.8
60.6
59.9
56.0
36.9
49.6

100
27.3
41.9
41.1
41.5
44.1
32.0
40.4

100
29.6
29.3
29.3
30.6
32.2
33.3

CgDapB
SaDapB
PaDapB

40.3
21.9
44.0

29.8
35.8
27.5

24.6
29.5
26.1

40.7
26.7
51.4

MtDapB

46.0

31.8

25.5

42.8

Gram Negative Bacteria
Ec
Ng
Nm
Ps
DapB
DapB
DapB
DapB

100
62.8
100
62.4
98.1
100
62.9
61.9
62.3
36.1
33.9
33.5
62.5
53.2
53.2
Gram Positive Bacteria
28.6
29.5
28.7
32.0
30.9
30.9
29.8
28.0
28.0
Other Bacteria
30.1
29.8
29.8

Tm
DapB

Vv
DapB

Cg
DapB

Sa
DapB

Pa
DapB

100
38.9
57.4

100
36.1

100

27.9
32.6
27.6

30.6
41.7
30

30.1
35.0
28.1

100
22.9
43.6

100
20.9

100

32.7

27.6

30.9

65.9

24.7

44.4

Mt
DapB

100

Table 1.4. Inhibitors of DapB. Compounds A-E are sulfonamide based inhibitors.
Compounds F-I were identified using high throughput screening 60. Compound J is the
cofactor-substrate complex mimic 61
Compound
Name

Structure

Ki (µM)

SO2NH2 O
O

A
H2NO2S

Cl

22.6

O

Cl
SO2NH2 O
O

B

35.4

O

H2NO2S

Cl
SO2NH2 O

C

42.3

O

H2NO2S

Cl
SO2NH2 O

D
H2NO2S

Cl
Cl
SO2NH2

E
S
O2

48.4

O

O

7.2

O
Cl

O
HN

S

F

160
O

F
F

Cl

F

S

G

45
S
N N

15

O

O

HN N

H

69

N
S

O

S
S

Br

N

I

58

O
O
HO
N

O

J

0.1
HO

S

N

HO

16

S

OH

1.9. FIGURES

Figure 1.1. Lysine biosynthesis pathway. Lysine biosynthesis via succinylase pathway
which is commonly found in Gram negative bacteria is shown 56.
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Figure 1.2. Two-dimensional projection of the CLANS clustering results. Proteins are
indicated by dots. Lines indicate sequence similarity detectable with BLAST and are
colored by a spectrum of shades of gray according to the BLAST P-value. Sequences
corresponding to structures in the PDB are indicated by blue dots, Sequence of NgDapB is
indicated by red dot 56. Dr. Karolina A. Majorek, Department of Molecular Physiology and
Biological Physics, University of Virginia prepared this figure.

18

Figure 1.3. Sequence alignment of all DapB’s that have their structures determined.
MtDapB; Mycobacterium tuberculosis (PDB ID: 1YL5), CgDapB; Corynebacterium
glutanicum (PDB ID: 5EER), AvDapB: Anabaena variabilis (PDB ID: 5KT0), CbDapB;
Coxiella burnetti (PDB ID: 5WOL), BhDapB; Bartonella henselae (PDB ID: 3IJP),
BtDapB; Burkholderia thailandensis (PDB ID: 4F3Y), NgDapB; Neisseria gonorrhoeae
(PDB ID: 6BDX), PsDapB; Pseudomonas aeruginosa (PDB ID: 4YWJ), VvDapB; Vibrio
vulnificus (PDB ID: 5US6), EcDapB; Escherichia coli (PDB ID: 1ARZ), TmDapB;
Thermotoga maritima (PDB ID: 1VM6), SaDapB; Staphylococcus aureus (PDB ID:
3QY9) 56, 63.
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Figure 1.4. Structure of bacterial DapB enzyme. A] Biological assembly of DapB
(EcDapB, PDB ID: 1ARZ). All monomers are shown in different colors in the tetramer. B]
Nucleotide binding domains (gray) and oligomerization domains (pale cyan) of DapB
enzyme. The central β- barrel formed by oligomerization domain of each monomer is
shown in cyan.
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Figure 1.5. Conformational changes in DapB enzymes. Superposition of DapB
structures in apo (grey) (PDB ID: 5TEK), NADH bound (green) (PDB ID: 5UGV) and
NADH, 2,6-PDC (cyan) (PDB ID: 5TJY) bound forms. The structures were superposed
using Molsoft ICM- Browser 64.
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CHAPTER 2
STRUCTURAL CHARACTERIZATION OF 4- HYDROXYTETRAHYDRODIPICOLINATE REDUCTASE FROM NEISSERIA
GONORRHOEAE
2.1. INTRODUCTION
Neisseria gonorrhoeae is an obligate human pathogen and is the leading cause of
communicable diseases globally

65

. It is a Gram negative, diplococcus, fastidious

microorganism that grows optimally at 35.5°C, pH 7.4. These values are very close to the
temperature and pH of human blood, which makes humans ideal hosts for this pathogen 66.
N. gonorrhoeae ranks second in terms of commonly reported notifiable disease in the
United States with an infection rate of 145.8 cases per 100,000 population reported last
year

67

. This rate in reality may be much higher due to underreporting and latent

asymptomatic infections 68. This bacterium commonly establishes infection in urethra and
the uterine cervix in men and women, respectively. Although, it does not infect other
organs commonly, it is known to cause arthritis-dermatitis syndrome, endocarditis,
osteomyelitis and meningitis in some patients

69

. In HIV infected individuals, N.

gonorrhoeae induces increase in the expression of viral RNA thus aggravating the infection
68

. In addition to HIV susceptibility, the infection can result in pelvic inflammatory disease,

which results in permanent fallopian tube scarring and blockage. Furthermore, it is
associated with subsequent infertility and ectopic pregnancies in women 70. Apart from
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adults, N. gonorrhoeae can also cause ophthalmia neonatorum, pharyngitis, rectal
infections and pneumonia in infants, if their mother is carrier (symptomatic or
asymptomatic infection) 71-72.
The first line of treatment for N. gonorrhoeae infection uses drugs like cefixime
and ceftriaxone that inhibit bacterial cell wall synthesis or ciprofloxacin and levofloxacin
that inhibit DNA replication 71. Unfortunately, these antibiotics are proving inadequate in
eradicating this pathogen due to its rapid development of drug resistance. Hence, the
current approved medication for gonococcal infections is combination of above mentioned
drugs with azithromycin

67

. However, there are several reports that indicate failure of

combination therapy in many patients

73

. It is also being speculated that gonococcal

infections will soon become untreatable 71-73. This situation rises the need for development
of new drugs and identification of new drug targets in the pathogen.
In this regard, the meso-Dap pathway is a promising drug target due to its
essentiality in microbial metabolism for lysine biosynthesis. Structural studies on DapB,
an important enzyme in the meso-Dap pathway from N. gonorrhoeae are described below.
2.2. CLONING
The sequence for 4-hydroxy-tetrahydrodipicolinate from N. gonorrhoeae
(NgDapB) gene was codon optimized for expression in Escherichia coli, synthesized, and
cloned into pJ411 plasmid vector system by ATUM, Inc. (Newark CA). The plasmid
contains an inducible T7 promoter, and kanamycin as selection marker. For ease of
purification a N-terminal hexahistidine tag (MHHHHHHSSGVDLGTENLYFQ/SGSG)
with Tobacco Etch Virus (TEV) cut site (marked with slash ) was added to NgDapB gene
sequence 74.

23

The plasmid was co-transformed with pGro7 chaperone plasmid (groES-groEL
chaperone system) (Takara Bio. Inc.) in E. coli BL21 (DE3) cells using heat shock method
75

. Co-expression experiments were done using arabinose (0.5 mg/L) as inducer for pGro7

plasmid. For starter cultures, a single colony was inoculated in 10 mL Luria Broth (LB)
with kanamycin (50 µg/mL) and chloramphenicol (34 µg/mL) and grown at 37°C
overnight. Starter cultures were inoculated in 1 L LB and grown to an O.D. of 0.6 at 37°C,
induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown overnight
at 16°C. The cultures were centrifuged at 9000g for 10 min and cell pellets were stored at
-80°C.
2.3. PROTEIN PURIFICATION
Cell pellets were suspended in binding buffer (50 mM Tris-HCl, 500 mM NaCl, 10
mM imidazole, pH 8.0) and lysed by sonication. Insoluble cellular debris was separated
from the supernatant by centrifugation at 37,780 g for 30 min at 4°C. The supernatant was
loaded onto Ni-NTA resin (Qiagen or Pierce) pre equilibrated with binding buffer. The
protein was eluted using 50 mM Tris-HCl, 500 mM NaCl, 300 mM imidazole, pH 8.0.
Elution fractions containing protein were identified by SDS-PAGE, pooled and dialyzed
overnight using SnakeSkin Dialysis Tubing (MW cutoff 10,000 Da) (ThermoFisher, Grand
Island, NY) in dialysis buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.5). The dialyzed
protein was concentrated and further purified by size exclusion chromatography (SEC)
using a GE Healthcare AKTA-Pure FPLC and HiLoad Superdex 200 column. The amount
of protein was determined by Bradford Assay 76 or A280 absorbance measurement using a
NanoDrop 2000c spectrophotometer 77. Hexahistidine tag (His-tag) was cleaved from the
protein by dialyzing the protein with TEV protease (with N-terminal His-tag) in 1:100
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(w/w) protease to protein ratio overnight at 4°C. TEV protease was separated from
NgDapB by passing the dialyzed mixture through Ni-NTA column. The non-tagged protein
was then collected, concentrated and purified with SEC as described above. The purified
protein was stored in 10 mM Tris, 150 mM NaCl, pH 7.5 or 25 mM HEPES, pH 7.5 at 80°C until further use.
2.4. CRYSTALIZATION
All the experiments were performed at room temperature using sitting drop vapor
diffusion setup and 96 well crystallization plates (Hampton Research, Aliso Viejo, CA).
Drops were formed by mixing crystallization condition and protein (10 mg/mL and 30
mg/mL) in 1:1 ratio. NgDapB with cleaved His-tag (cutNgDapB) stored in 10 mM Tris,
150 mM NaCl, pH 7.5 (apo structure) or 25 mM HEPES, pH 7.5 (co-crystallization with
ligands) was used for crystallization. Well diffracting crystals for apo protein were grown
from Hampton Index Screen condition, 0.1 M Bis-Tris pH 6.5 and 2.0 M ammonium
sulfate. Crystal structures of NgDapB bound to NADH; NADH, 2,6-PDC and NADH, 2,5FDC were obtained from crystals grown in Hampton Index Screen condition, 60 %
Tacsimate, pH 7.0. All the crystals were cryo-cooled in liquid nitrogen for X-ray diffraction
experiments.
2.5. DATA COLLECTION AND STRUCTURE DETERMINATION
Diffraction data was collected using South Regional Collaborative Access Team
(SER-CAT) 22ID and 19BM beamlines at Advanced Photon Source (APS), Argonne
National Laboratory (Lemont, IL). HKL-2000/3000 software package was used to process
diffraction images 78. Data collection and refinement statistics are shown in Table 1A and
1B. Structures were solved by molecular replacement using MOLREP
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79

integrated with

HKL-3000

80

. E. coli DapB (PDB ID 1ARZ) was used as a search model for the apo

structure. The apo structure for NgDapB was used as starting model for remaining
structures. The initial model for apo structure was rebuilt using BUCCANEER 81 whereas
ARP/wARP 82 was used to rebuild models for all the other structures. REFMAC 83, HKL3000 as well as various programs from the CCP4 package

84

were used for data analysis

and refinement. For apo structure and NADH bound structure, Non-crystallographic
symmetry was used in all the refinements, additionally TLS was employed during the last
stages of refinement. TLS motion determination server was used to partition protein chains
into rigid bodies undergoing vibrational motion

85

. In case of high resolution structures

(NgDapB in complex with NADH and 2,6-PDC or NADH and 2,5-FDC) anisotropic Bfactor model was employed during last refinement stages. PARVATI server was used for
validation of the anisotropic B-factors

86

. COOT

87

was used for model rebuilding and

validation. MOLPROBITY was used as a final validation tool for the structures 88.
2.6. STABILITY OF NgDapB
Recombinant NgDapB protein has an N-terminal His-tag for ease of purification.
Researchers have expressed contrasting views on alteration of stability, activity, structure
and physiological role of the recombinant protein due to the presence of His-tag. Some
studies support the hypothesis that His-tag does not affect the protein in any way 89. On the
other hand, there are reports in literature that bring forward a change in oligomerization
state and activity of protein in presence of His-tag 90-91. It appears that the influence of Histag changes with different proteins. Hence, stability of NgDapB with His-tag (HisNgDapB) and without His-tag (cutNgDapB) over a range of pH and salt concentration was
tested using Differential Scanning Fluorimetry (DSF). The stability of both the forms of
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protein was tested between a pH range of 4.0-9.5 and a salt range (sodium chloride) of 0.01.0 M. Buffers used for various pH ranges were acetate (pH 4.0-5.0), Bis-Tris (pH 5.5-6.5),
Tris-HCl (pH 7.0-8.0) and CHES (pH 8.5-9.5). Buffer strength was 50 mM for all the
conditions. SYPRO® Orange Dye (ThermoFisher, Waltham, MA) was diluted 1:1000 in
1.0 mL of 2 mg/mL protein. This solution was mixed with each screening condition in 1:1
ratio for a 20 µL total reaction volume in a Bio-Rad Hardshell 96-well RT-PCR plate
(Hercules, CA). The plate was sealed using Microseal PCR Plate Sealing Film (Bio-Rad,
Hercules, CA). All experiments were performed in triplicate. An experimental protocol to
increase the temperature of the 96 well plate from 30-90°C in 2°C increments after one
minute intervals was used. Bio-Rad CFX Manager software was used to determine the
inflection point of melting curves.
The presence of His-tag did not show a major change in the stability of NgDapB in
terms of melting temperature (Tm). Both cutNgDapB and His-NgDapB showed highest
Tm of 76°C. The best buffering conditions for both proteins were between pH 7.5-9.5
(Figure 2.1). Change in salt concentration did not affect the stability of both forms of
protein significantly.
2.7. STRUCTURE OF apo-NgDapB
The crystal structure of apo-NgDapB was determined at 1.85 Å resolution (PDB
ID: 6BDX). The protein crystallized with one chain in the asymmetric unit (AU) in I222
space group with overall R and Rfree values of 0.169 and 0.209 respectively (Table 2.1).
However, the biological assembly of apo-NgDapB exhibits tetrameric arrangement, which
is a common characteristic of all bacterial DapB’s. Each protein chain is composed of 267
amino acid residues. The interfaces between a single protein chain and two neighboring
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chains from the tetrameric assembly are large and there areas are 1460Å2 and 870Å2
respectively 56. Apo-NgDapB (PDB ID: 6BDX) shares the highest sequence similarity with
DapB from N. meningitides (PDB ID: 5UGJ, chain A) with rmsd (root mean square
deviation) of 0.90 Å over 246 Cα atoms. This is followed closely by DapB’s from other
bacteria like E. coli (PDB ID: 1ARZ, chain A; rmsd 1.2 Å over 248 superposed Cα atoms),
P. aeruginosa (PDB ID: 4YWJ, chain A; rmsd 1.3 Å over 250 superposed Cα atoms) and
B. thailandensis (PDB ID: 4F3Y ,chain A; rmsd 1.0 Å over 249 superposed Cα atoms)
(Figure 2.2).
In terms of domain architecture, residues 1-126 and 237-268 form the nucleotide
or cofactor/coenzyme binding domain. The cofactor binding domain adopts Rossmann
fold: a super secondary structure that is characteristic to all bacterial DapB’s. In case of
NgDapB and DapB from C. glutamicum, the structure consists of seven parallel β strands
in the center flanked by six α-helices

51, 56

. On the other hand, the Rossmann fold is

composed of six β-strands and four α-helices in DapB from M. tuberculosis 92 and seven
β-strands and four α-helices in DapB from E. coli

59

and S. aureus 93. Another variation

observed in the cofactor binding region within DapB homologs is the length of the Nterminal long loop. In case of NgDapB, this loop extends from Ser38 to Gly56. This is
comparable to corresponding loop formed by Glu40-Gly59 in E. coli DapB and Lys35Gly54 in B. henselae DapB 94. A much shorter loop is seen in DapB from S. aureus (Thr33Pro39) 93.
The oligomerization domain, which is the second domain architecture present in
DapB’s is composed of residues 127-236 in NgDapB. This domain consists of two αhelices and four β-strands. The β-strands from each monomer interact with each other to
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form a central β-barrel that forms the base for the tetrameric assembly. Similar to the
variability seen in the cofactor binding domain, oligomerization domain also shows
differences in the secondary structure elements composition. E. coli, M. tuberculosis and
S. aureus DapB domains are composed of two α-helices and four β-strands just like
NgDapB whereas oligomerization domain of C. glutamicum DapB is made up of two αhelices and five β-strands 51, 59, 92-93. Differences are also seen in the length of the C-terminal
long loop. This loop is formed by amino acids Leu193- Ser201 in NgDapB and Leu182Gly204 in E. coli. On the other hand, this loop adopts a different conformation in M.
tuberculosis DapB 92 and is completely absent in DapB from T. maritima 49.
2.8. STRUCTURES OF NgDapB WITH LIGANDS
NgDapB was co-crystallized with its cofactor NADH and small molecules 2,6-PDC
and 2,5-FDC. Ligand bound structures of NgDapB were obtained from protein stored in
25 mM HEPES, pH 7.5 buffer. For all the structures, the protein crystallized in P21212
space group with two molecules in the AU and very similar unit cell parameters (Tables
2.1 and 2.2). Ile8, Val18, His137, Leu132, Thr133, Ile152, Ser201 and Met260 are in
double conformation in all the three structures. The active site (coenzyme and
substrate/inhibitor site) for NgDapB is shown in Figure 2.3. The coenzyme/ cofactor
(NADH) bound structure was determined at 1.4 Å resolution. The overall R and Rfree values
were 0.141 and 0.167 respectively. NADH is bound to active sites in both the molecules in
AU. Each active site also shows a bound acetate ion. These ions are bound in the same
position as that of substrate. Additionally, two sodium ions are also modeled in the
structure but are most likely artifacts of crystallization and have no physiological
significance. The cofactor binds near a highly conserved GXXGXXG motif in DapB. This
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motif is composed of

10

Gly-Ala-Asn-Gly-Arg-Met-Gly16 in NgDapB. Amongst these

residues, Gly13 (along with Glu36) and Arg14, Met15 (along with Arg78) form hydrogen
bond interactions with the phosphate moieties and ribose of adenine respectively (Figure
2.5). The corresponding E. coli DapB motif 12Gly-Ala-Gly-Gly-Arg-Met-Gly18 also show
similar interactions with NADH

95

. NADH is further held in the active site pocket by

additional interactions with the main chain residues. Nicotinamide ring of NADH interacts
with Gly99 and Ala123 whereas Lys160 and Thr101 interact with ribose of adenine. In E.
coli structure (PDB ID: 1ARZ) along with these residues (corresponding E. coli residues:
Gly102, Ala127, Lys163, Thr80) additional interaction with Phe129 is also seen. In
NgDapB, the adenine ring does not interact with the main chain residues (Figure 2.5). On
the other hand, in EcDapB, adenine ring interacts with Gly84 and Thr80. This difference
may be due to the positioning of NADH in the active site. In EcDapB, the adenine ring is
bent towards the main chain in comparison to NADH bound to NgDapB.
The substrate and inhibitor binding site is located near a highly conserved region in
the oligomerization domain of the enzyme
154

59

. This region is composed of residues

EGHHRHKVDAPSGTA168 in NgDapB. The residues shown in bold are conserved in

all the DapB homologs that have their structures determined. On the other hand, Ala168 is
conserved in all the homologs except BhDapB and SaDapB (Figure 1.3). High resolution
structures of NgDapB bound to NADH, 2,6-PDC and NADH, 2,5-FDC were solved at
1.25Å and 1.27Å respectively. As described in Chapter 1, 2, 6-PDC is a known inhibitor
of DapB. We co-crystallized NgDapB with a novel potential inhibitor, 2, 5-FDC. The
NADH, 2,6-PDC structure has over all R value 0.127 and Rfree value 0.165 whereas the
NADH, 2,5-FDC structure has R value 0.124 and Rfree value 0.164. The electron density
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map of NADH and 2,5-FDC is shown in Figure 2.3. 2,5- FDC binds NgDapB in the exact
manner as 2,6-PDC. Both the ligands interact with the nicotinamide ring of the cofactor
and show several interactions with residues in the conserved oligomerization motif of the
main chain. The carboxylic acid groups of both the ligands from hydrogen bonds with
His157, Lys160, Gly166 and Thr167 (Figure 2.6). The same residues interact with 2,6PDC in the active site of EcDapB 95.
2.9. CONFORMATIONAL CHANGES IN NgDapB
Similar to other bacterial homologs, NgDapB also undergoes a change in
conformation upon ligand binding (Figure 2.7). A shift in the nucleotide binding domain
is seen due to bending of residues that is induced due to ligand binding. Conformational
changes in different NgDapB structures were studied using the DynDom server
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. The

results are shown in Figure 2.8. Conformational change analysis in DapB homologs
indicate that binding of both cofactor and substrate/ inhibitor to apo structure (open form
of DapB) induces a significant conformation change (>30°, compared to nucleotide binding
domain in apo structure) resulting in closure of DapB monomer. In NgDapB, this change
is 37.5°. Similar change of 31.5° and 31.9° occurs in EcDapB and MtDapB (Figure 4.2)
respectively. The bending region analysis reveals that the change is induced due to shifting
of residues Asn124-Met128 and Gly325-Met238 in NgDapB. Corresponding residues are
Asn128-Val131, Ser214-Met241 in EcDapB and Asn104-Met113, Arg214-Gly220 in
MtDapB. DapB’s also show a minor conformational change (<10°) induced by binding of
just the cofactor resulting in partial closure of the DapB monomer. However, in case of
NgDapB, this change is not observed. The NADH bound structure is in close conformation.
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This anomaly is due to the presence of acetate ion that mimics the substrate molecule in
the active thus inducing complete closure of the monomer.
2.10. DISCUSSION
Antibiotic resistance in N. gonorrhoeae is a major healthcare issue worldwide and
hence identification of new drug targets for this pathogen is essential. The potential of
DapB enzymes as novel drug targets is discussed in the previous chapter. Results for
recombinant expression, purification, and structural characterization of DapB from N.
gonorrhoeae are described in this chapter. Initially, the protein was expressed alone in E.
coli BL-21 cells. Despite being expressed in significant quantities, the protein could not be
used for further studies because it was not folded correctly as indicated by SEC. After
several trials, the protein was obtained in the desired oligomerization state when coexpressed with pGro chaperone plasmid.
After optimizing the expression and purification, NgDapB was successfully
crystallized in several forms. The apo form of the protein crystallized with the N-terminal
His-tag attached to it, and it took several months for the protein to crystallize. Crystal
structure of apo-NgDapB was determined at 1.85 Å resolution. The biological assembly of
NgDapB is tetrameric which is consistent with all bacterial DapB’s. This is the first crystal
structure of DapB from N. gonorrhoeae in Protein Data Bank (PDB ID: 6BDX). The
protein was stored in Tris buffer when it was crystallized in apo form. Subsequent studies
showed that removal of His-tag and transferring the protein in HEPES buffer significantly
reduced the time needed to obtain well diffracting crystals (several months to 1-2 weeks).
Additionally, several structures of NgDapB bound to cofactors and substrate analogs were
obtained. The structure of NgDapB bound to its cofactor, NADH, and substrate analog,
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2,6-PDC, was determined at 1.25 Å. This is the highest resolution structure that has been
reported in PDB for any DapB. In addition to 2,6-PDC, structure of NgDapB bound to
NADH and 2,5-FDC was determined at 1.27 Å resolution. 2,6-PDC has already been
identified as a substrate analog and inhibitor of DapB. Here, we have successfully cocrystallized 2,5-FDC with NgDapB. Both 2,6-PDC and 2,5-FDC bind NgDapB in a very
similar manner which may indicate that 2,5-FDC is a novel potential inhibitor of NgDapB.
Structural studies done here show that NgDapB undergoes a major conformational change
upon binding of cofactor and substrate. These observations open a new avenue for drug
design. Studies can be directed to develop inhibitors that trap the protein in the
conformation that is unfavorable for enzyme reaction. Availability of high resolution
structures of proteins is an integral part of structure based 97 drug design. These structures
can be used for virtual screening of compound libraries to identify novel potential
inhibitory ligands. Structural analysis of protein – ligand complexes gives further
information about the way protein interacts with the ligand and may give clues about the
mechanism of inhibition.
One of the major challenges with DapB enzymes is the unstable nature of the
substrate. Initially, dihydrodipicolinate was believed to be the true substrate for the enzyme
20

. Subsequent studies revealed that (2S, 4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate may

be the true substrate for the enzyme. There is also a speculation that this enzyme might act
as a hydratase 98. Moreover, there is no information about the reaction mechanism for these
enzymes. Hence, structural studies are important particularly for DapB’s since they may
provide insights about the enzyme reaction mechanism. Analysis of the NADH-bound
structure identifies several residues that may play a role in hydrogen bonding with the
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cofactor. Some residues like Lys160 and Thr101 are conserved in all the DapB’s that have
their structures determined. The acidic Glu36 and basic Arg14 are either conserved or have
a corresponding acidic or basic residue in the majority of DapB’s co-crystallized with
cofactors. These residues may be important in cofactor positioning in the active site.
Furthermore, structural data shows that Lys160 also interacts with substrate/substrate
analog and hence may play an important role in the enzyme reaction.
In conclusion, the studies presented here not only provide a platform for drug
designing but also present a novel compound, 2,5-FDC, which binds NgDapB in the active
site and may be studied further for its inhibitory potential.
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2.11. TABLES
Table 2.1. Data collection, processing and refinement statistics for apo and NADH
bound structures. Parameters for the highest resolution shell are in parenthesis.
Protein

Apo NgDapB (PDB ID:

NgDapB bound toNADH

6BDX)

Diffraction source (APS Beamlines)

22ID

19BM

Wavelength (Å)

1.000

0.97

Temperature (K)

100

100

Detector

MX300HS

MX300HS

Space group

I222

P21212

a, b, c (Å)

57.8, 71.7, 138.4

92.4, 92.9, 60.2

α, β, γ (°)

90, 90, 90

90, 90, 90

Resolution range (Å)

40.00-1.85 (1.88-1.85)

40.00-1.40 (1.42-1.40)

Solvent content

0.67

0.44

No. of unique reflections

25492 (1715)

92518 (2551)

Completeness (%)

99.9 (100.0)

90.6 (50.9)

Redundancy

7.9 (7.8)

7.0 (3.7)

〈 I/σ(I)〉

48.1 (3.38)

57.3 (5.0)

Rmeasure

0.067 (0.757)

0.052 (0.306)

Rp.i.m.

0.024 (0.270)

0.018 (0.148)

CC1/2

(0.863)

(0.940)

Rcryst

0.169 (0.216)

0.14

Rfree

0.209 (0.267)

0.17

Bonds (Å)

0.021

0.022

Angles (°)

1.9

2.2

Average B factors (Å2)

39.8

14.9

Favored (%)

98

98.1

Allowed (%)

100

100

Outliers (%)

0

0

R.m.s. deviations

Ramachandran plot
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Table 2.2. Data collection, processing and refinement statistics for NgDapB
structures. Parameters for the highest resolution shell are in parenthesis.
NgDapB with NADH,

NgDapB with NADH, 2,5-

2,6-PDC

FDC

Diffraction source (APS Beamlines)

22ID

22ID

Wavelength (Å)

1.000

1.000

Temperature (K)

100

100

Detector

Eiger 16M

Eiger 16M

Space group

P21212

P21212

a, b, c (Å)

92.7, 92.7, 60.2

92.7, 92.7, 60.5

α, β, γ (°)

90, 90, 90

90, 90, 90

Resolution range (Å)

50.00-1.25 (1.27-1.25)

50.00-1.27 (1.29-1.27)

Solvent content

0.44

0.44

No. of unique reflections

141434 (6168)

130289 (6579)

Completeness (%)

98.6 (87.0)

94.6 (96.6)

Redundancy

6.6 (4.7)

6.7 (6.6)

〈 I/σ(I)〉

46.9 (3.6 )

33.2 (3.4)

Rmeasure

0.044 (0.439)

0.070 (0.558)

Rp.i.m.

0.017 (0.187)

0.027 (0.204)

CC1/2

(0.922)

(0.930)

Rcryst

0.127 (0.231)

0.124 (0.189)

Rfree

0.165 (0.270)

0.164 (0.213)

Bonds (Å)

0.010

0.018

Angles (°)

1.6

1.9

Favored (%)

98.5

98.5

Allowed (%)

100

100

Outliers (%)

0

0

Protein

R.m.s. deviations

Average B factors (Å2)
Ramachandran plot
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2.12. FIGURES

Figure 2.1. Stability studies on NgDapB. Stability of cutNgDapB and His-NgDapB
proteins was studied over a range of pH and salt (blue) concentrations. The numbers in
black indicate the melting temperatures (Tm) of the proteins at different conditions and the
cells are colored using a white (low Tm) and green (high Tm) gradient 99.
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Figure 2.2. Structure of NgBapB (A) and EcDapB (B) with sequence conservation
mapped on protein structure. The residues marked in red are completely conserved
among DapB’s that have their structure determined. The residues marked in blue are
conserved in at least 10 out of 12 DapB’s that have their structure determined. Coenzymes,
2,6-pyridine dicarboxylic acid (green) and the catalytic lysine residues are shown in stick
representation 56.
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Figure 2.3. Active site pocket of NgDapB. Ligands in the active site are in green. NgDapB
monomer is shown in surface representation model with surface charges mapped. PyMol
was used to calculate the surface charges.
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Figure 2.4. Electron density map of active site molecules. The structure of NgDapB
bound to NADH and 2,5-FDC was solved at 1.27 Å. 2Fo-Fc map (contoured at 1.5 σ) of
the active site bound NADH and 2,5- FDC is shown.
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Figure 2.5. Cofactor/coenzyme binding site of NgDapB. Active site residues and NADH
are shown in grey and green respectively. Black dashed lines represent hydrogen bonds
between NADH and amino acids. The numbers show distances in Å.
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Figure 2.6. Substrate/ Inhibitor binding site of NgDapB. Amino acid residues are in
grey and the ligands are in green. Black dashed lines indicate protein ligand interactions
mediated by H-bonds. A] 2,6-PDC. B] 2,5-FDC. The numbers show distances in Å.
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Figure 2.7. Conformational changes in NgDapB. Apo structure of NgDapB is in green
and the ligand bound structure is in cyan.
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6DBX:
NADH
NADH,
2,6-PDC
NADH,
2,5-FDC

Chains
A
A
B
A
B
A
B

6BDX
A
0
37.3
37.1
37.2
37.1
37.3
37.2

A

NADH
B
0
0.5
0
0
0
0

NADH,2,6-PDC
A
B

0
0
0
0
0

0
0
0
0

0
0
0

NADH, 2,5FDC
A
B

0
0

0

Figure 2.8. Protein domain motion analysis of NgDapB structures. Conformational
changes between different chains in apo-NgDapB structure (PDB ID: 6BDX) and ligand
bound structures were analyzed using DynDom server 96. The numbers indicate change in
the angle of rotation between two chains. The chains that show significant change in
conformation are highlighted in green.
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CHAPTER 3
MUTATION STUDIES ON 4-HYDROXYTETRAHYDRODIPICOLINATE REDUCTASE ENZYME
3.1. INTRODUCTION
The sequence analysis and general structure of DapB is described in Chapter 1. The
high sequence identity shared between bacterial homologs indicate that these enzymes may
be good targets for development of broad spectrum antibiotics. However, in depth
knowledge about enzyme function is a prerequisite for inhibitor development. In this
regard, there is limited data available for DapB enzymes. This chapter focuses on the active
site of DapB enzymes. The active site or the cofactor and substrate binding pocket of DapB
is aligned with several residues from both domains of DapB enzymes. The first forty amino
acids from the nucleotide binding domain, including the conserved GXXGXXG motif,
form one side of the active site. The other side of the active site is formed by a highly
conserved region from the oligomerization domain (Figure 3.2). DapB’s utilize NAD(P)H
as cofactor (substrate) in the reaction that yields 2,3,4,5-tetrahydrodipicolinate. The
interaction of DapB with its cofactor(s) has been evaluated using thermodynamic analysis
and enzymatic assays

49, 95

. These studies revealed that DapB homologs have different

preferences for their cofactors

49, 52, 56, 92-93, 95

. Studying the hydrogen bond interactions

between the cofactor and the main chain of the protein may help in identification of
residues important for cofactor binding. Hence, several groups carried out crystal structure
studies of DapB’s in complex with cofactors. The sequence alignment of N-terminal
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residues near nucleotide binding site in DapB’s that have their structures determined in
PDB is shown in Figure 3.1. Reddy et al. 95 published the first crystal structures of EcDapB
with its cofactors. The interactions between the main chain and nucleotide cofactors
identified two residues that may be critical for nucleotide preference. One is an acidic
residue, Glu38, which interacts with ribose of adenine, and the other is a basic residue,
Arg39, that interacts with ribose phosphate (Figure 3.3 A) 95. Subsequent data published
on other DapB homologs suggested that presence of these acidic and basic residues are not
the deciding factors for nucleotide preferences 92. For example, MtDapB lacks the basic
residue that stabilizes the ribose phosphate of NADPH in EcDapB. Hence, MtDapB should
have significant preference for NADH. Surprisingly, MtDapB exhibits only moderate
preference for NADH (KM values in presence of NADH and NADPH are 3.2 ± 0.4 µM and
11.8 ± 1.5 µM respectively) 92. Moreover, structure analysis of NADPH bound MtDapB
showed that NADPH primarily forms hydrogen bond interactions with the main chain
residues through nicotinamide and ribose of nicotinamide moieties (Figure 3.3 B)
Another study was conducted on PaDapB
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92

.

. The sequence alignment shows that this

enzyme has Asp36 and His37 corresponding to Glu38 and Arg39 in EcDapB. Therefore,
it is expected that PaDapB will bind both cofactors with more preference for NADPH.
However, cofactor binding studies using isothermal titration calorimetry (ITC) have shown
that it binds NADPH only 52. These studies clearly indicate that other residues lining the
active site pocket influence the cofactor preference for DapB’s.
One approach to identify these residues is to generate active site mutants and assess
their effect on binding of cofactors. There is limited data on mutation studies in DapB.
Cirilli et al. 92 evaluated the effect of Lys9 and Lys11 (Lys to Ala) mutation on nucleotide
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specificity of MtDapB using enzyme kinetics. Based on these experiments, it was
suggested that both these mutations significantly increase the enzymes preference for
NADH over NADPH 92. A second study was done on SaDapB 93. Here another residue,
Lys35, was identified, which may perform an equivalent role to Arg39 in EcDapB
Recently, Lee et al.
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93

.

published mutation studies on PaDapB showing that mutation of

His37 (equivalent of Arg39 in EcDapB) results in complete loss of binding to NADPH
whereas mutation of Lys36 results in reduced affinity for NADPH 52.
This chapter describes mutation and crystal structure studies on three DapB
homologs (NgDapB, VvDapB and MtDapB). Aim of the study is to understand the role of
different active site residues in binding of the cofactor and substrate/substrate analogs.
3.2. SITE DIRECTED MUTAGENESIS OF DapB HOMOLOGS
The residues that were mutated in NgDapB are shown in Figure 3.2 and the
corresponding residues in MtDapB and VvDapB are listed in the box in Figure 3.2. The
selection of residues for mutation was based on the roles that they play in the active site.
Lys160 (NgDapB) was selected because it interacts with both the cofactor and the
substrate/substrate analog. His157 was mutated since it interacts only with the substrate/
substrate analog. Residues Asp75, Asn125, His156 and Asp162 do not from hydrogen
bonds with ligands (cofactor or substrate/substrate analog) but are in close vicinity of the
ligands. These residues were selected to assess the effect of the environment on binding of
ligands. In addition, all selected residues are completely conserved in DapB’s that have
their structure determined and reported in the PDB.
The recombinant NgDapB plasmid is described in Chapter 2. Similar to NgDapB,
VvDapB (Vibrio vulnificus strain CMCP6 (Uniprot: Q8DEM0) and MtDapB
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(Mycobacterium tuberculosis HKBS1 (Uniprot: W6GQ56) genes were cloned into
pJExpress 411 plasmid vector by ATUM, Inc. (Newark, CA). Both the genes were codon
optimized for expression in E. coli and had an additional N-terminal His-tag followed by a
TEV protease cut site identical to recombinant NgDapB. pJExpress 411 plasmid has a
selectable kanamycin resistance marker and isopropyl β-D-1-thiogalactopyranoside
(IPTG) inducible T7 promoter. 100.
Active site mutants of NgDapB, MtDapB and VvDapB were generated using site
directed mutagenesis. NEBaseChanger (v1.2.8) (New England Biolabs, Ipswich, MA)was
used to design primers for generating mutations in DapB homologs. Primers used for
mutagenesis are listed in Table 3.1. Thermal cycling reaction conditions were based on
NEB Q5 polymerase protocol. 1.0 ng of template was used for all reactions. GC enhancer
was added to reactions using primers sets with more than 5°C difference in Tm. PCR
products were ligated using the NEB Q5 polymerase protocol. Post ligation, reaction
mixtures were transformed into competent E. coli DH5-α cells and spread onto LB-Agar
plates containing appropriate antibiotic.
Plates were incubated at 37˚C overnight. Individual colonies were inoculated in 5.0
mL LB containing appropriate antibiotic and grown at 37˚C overnight (about 16 hours)
with shaking. Plasmid isolations were done using ThermoFisher GeneJET Plasmid
Miniprep Kit (Grand Island, NY) following the manufacturer’s protocol. All plasmids were
eluted with 40 µL of nuclease-free water. Plasmids were then sent to Eton Bioscience
(Research Triangle Park, NC) for sequencing with T7 forward and T7 reverse primers to
confirm presence of mutation.
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3.3. PROTEIN EXPRESSION AND PURIFICATION
NgDapB mutants were co-expressed with pGro plasmids and purified similarly to
native NgDapB described in Chapter 2. MtDapB and VvDapB mutants were transformed
in E. coli BL21 (DE3) cells using heat shock method 75. Starter cultures were grown by
inoculating single colonies containing respective plasmids in10 mL of LB with kanamycin
(50 µg/mL) and were grown at 37° C overnight. Next day starter cultures were grown in
1L LB with kanamycin (50 µg/mL) to an OD600 of 0.6-0.8. This was followed by induction
of protein expression by the addition of 0.5 mM IPTG and growth at 16° C overnight. The
proteins were purified as described previously 99. Briefly, bacterial cells were collected and
suspended in lysis buffer (50 mM Tris, 500 mM NaCl, and 10 mM imidazole, pH 8.0)
supplemented with a protease inhibitor cocktail (Pierce, Rockford, IL). The cells were
lysed by sonication and the supernatants containing protein were separated from cell debris
by centrifugation (35,250 g for 30 min at 4°C). The supernatants were then loaded onto NiNTA agarose bead columns (Qiagen or Pierce). The columns were washed with 50 mM
Tris-HCl, 500 mM NaCl, and 30 mM imidazole, pH 8.0. The proteins were eluted with 50
mM Tris-HCl, 500 mM NaCl and 300 mM imidazole, pH 8.0 and dialyzed overnight in 10
mM Tris-HCl, and 150 mM NaCl, pH 7.5. Dialyzed proteins were concentrated and
purified further by size exclusion chromatography using a GE Healthcare AKTA-Pure
FPLC and HiLoad Superdex 200 column.
3.4. CRYSTALLIZATION, DATA COLLECTION AND STRUCTURE
DETERMINATION
Sitting drop vapor diffusion technique was used for all crystallization experiments.
Crystallization trials were done in 96 well crystallization plates (Hampton Research, Aliso

49

Viejo, CA) using commercially available Index (Hampton Research, Aliso Viejo, CA) and
Wizard Classic (Rigaku Reagents, Bainbridge Island, WA) screens. Protein and
crystallization condition mixed in 1:1 ratio formed the crystallization drop. Ligands were
premixed at 10 mM concentrations with the protein for co-crystallization experiments.
Proteins stored in 25 mM HEPES, pH 7.5 were used for NgDapB mutants around 30
mg/mL concentration. For VvDapB and MtDapB mutants, proteins stored in 10 mM TrisHCl, 150 mM NaCl, pH 7.5 were used at around 15 mg/mL concentrations. Table 3.2 lists
the crystallization conditions from which well diffracting crystals for different mutants
were grown. All the crystals were cryo-cooled in liquid nitrogen for X-ray diffraction
experiments.
Structural Biology Center (SBC) and the South East Regional Collaborative Access
Team (SER-CAT) beamlines at Advanced Photon Source (APS), Argonne National
Laboratory (Lemont, IL) were used for X-ray diffraction experiments. Data sets were
processed using HKL-2000 80 and structures were solved by molecular replacement using
MOLREP 79 integrated with HKL-3000 80. EcDapB (PDB ID: 1ARZ) was used as starting
model for VvDapB and MtDapB mutants where as NgDapB (PDB ID: 6BDX) was used
as starting model for NgDapB mutants. Refinement was done using HKL-3000 integrated
with REFMAC5

83

, various components of the CCP4 package
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and TLS

85

. Manual

building was done using COOT 101. MOLPROBITY 88 and COOT were used as validation
tools.
3.5. STRUCTURES OF MUTANTS
The mutant DapB’s were crystallized in their apo form to confirm that the changes
induced by the mutation are local and do not induce any major change in the overall
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conformation of the protein. Three mutants of NgDapB were successfully crystallized in
their apo form. All the mutants crystallized in I222 space group just as native NgDapB
(Table 3.2). Structures of NgDapB N125A and N125D mutants were solved at 1.8 Å and
2.35 Å resolution respectively whereas the structure of NgDapB H157A mutant was solved
at 1.85 Å resolution. Structurally, all the mutants are very similar to the native NgDapB
and superpose with rmsd values of 0.4Å (NgDapB N125D), 0.6Å (NgDapB N125A) and
0.5Å (NgDapB H157A) over 269 Cα atoms (Figure 3.4).
Four mutants of MtDapB were successfully crystallized in their apo form.
Structures of MtDapB D51A (resolution 2.7Å), K136A (resolution 2.2Å) and H133A
(resolution 2.5Å) mutants were solved in the same space group (P21212) as that of native
protein. MtDapB D138A mutant was crystallized in two crystal forms. One structure was
solved in C2221 (crystal form A) and the other was solved in P21212 (crystal form B) at 2.8
Å and 2.0 Å resolutions respectively. Despite the differences in crystal packing (different
space groups), the overall structures are very similar and superpose with an rmsd of 0.8Å
over 246 Cα atoms. Both the crystal forms as expected are very similar to the apo form of
native MtDapB (PDB ID: 5TEK) and superpose with rmsd vales of 0.7Å and 0.4Å
respectively over 249 Cα atoms.
3.6. STRUCTURES OF MUTANTS WITH LIGANDS
The VvDapB lysine mutant (K159A) was co-crystallized with NADH. The
structure was solved at 2.0 Å resolution with R and Rfree vales 0.207 and 0.243 respectively.
Native VvDapB has been co-crystallized with cofactors and substrate analogs in P21 (PDB
IDs: 5US6, 5TEN), C2 (PDB ID: 5TEJ) and P21212 (PDB ID: 5TEM) space groups. The
lysine mutant crystallized in the I222 space group with one molecule in the asymmetric
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unit. Conformational change analysis using DynDom server indicated that this structure is
in closed conformation. This complete closure is most likely be due to the presence of a
sulfate ion near the active site. This structure shows highest structural similarity with
VvDapB structure bound to NADH and 2,6-PDC (PDB ID: 5TEM). These structures
superpose with an rmsd value of 0.4Å over 266 Cα atoms. Both the structures also show
very similar interface areas of 1580 Å2 (native) and 1575 Å2 (mutant) between protein
chains. However, analysis of the cofactor binding shows some differences. Even though,
general binding of NADH is similar, the phosphate groups in the cofactor are oriented
differently (Figure 3.5). Some changes are also seen in the interaction of the cofactor with
the main chain residues (Figure 3.6). In the native structure, Lys159 primarily forms
hydrogen bonds with the ribose of adenosine along with Thr100. In the mutant structure,
this ribose interacts with Thr100 only. The nicotinamide moiety forms hydrogen bonds
with Tyr125 in the native protein whereas in the mutant structure, a different residue
Pro123 hydrogen bonds with the nicotinamide fragment. Another difference is seen in the
hydrogen bonds formed by ribose of adenine. In the native structure, Arg35 primarily forms
hydrogen bonds with the ribose of adenine. In the mutant structure, Glu34 forms hydrogen
bonds with the ribose of adenine. Structural studies do show some changes in the hydrogen
bond network that mediate interactions between the cofactor and protein. However, further
biochemical analysis is essential to understand the implications of these changes in the
affinity and kinetics of the enzyme.
Crystallization trails were also done to co-crystallize other mutants with cofactors
and substrate analogs. The conditions from which crystals were grown are listed in Table
3.3. However, X-ray diffraction experiments showed that they were of poor diffraction
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quality and need optimization. All the mutants crystallized within a pH range of 5.5-8.5.
The amount of PEG 3350 present in the crystallization condition may be an important
factor in obtaining well diffracting crystals.
3.7. DISCUSSION
DapB enzymes are being studied for over two decades as drug targets

57, 102

.

Surprisingly, still very little is known about the enzyme reaction. In depth, understanding
of the active site of an enzyme is imperative to gain insights about the mechanism of
enzyme reaction. In the case of DapB’s the mechanism of enzyme reaction is unknown.
Another enigma associated with DapB’s is the cofactor preference. Studies on different
DapB homologs have indicated that active site residues that do not directly interact with
cofactor or substrate may influence the rate of enzyme reaction 92. With the aim of finding
answer to the cofactor preference and, to identify the most important active site residues
for enzyme reaction, several highly conserved residues were mutated and structural studies
on these DapB mutants was done. Mutation studies were carried out on different DapB
homologs to confirm that the observed changes due to mutations are not restricted to one
particular DapB. Mutation studies on DapB from N. gonorrhoeae, M. tuberculosis and V.
vulnificus are described in this chapter. NgDapB shares high sequence identify with
EcDapB, which is the most, studied DapB. VvDapB on the other hand was selected due to
the natural antibiotic resistance present in the organism. MtDapB shares the least sequence
identity with these bacterial homologs. Due to the diverse nature of bacterial DapB sources
under study, we expect that the results obtained from these experiments can be applied to
majority of bacterial homologs.
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Fourteen mutants were successfully generated, expressed and purified in high
yields (20-30 mg/mL). Most of the mutants were crystallized in their apo form. The results
indicate that these mutations do not influence the overall structure of the protein. This
indicates that the changes induced by these mutations are local and hence these mutants
can be used for further studies to evaluate their mechanistic effects. In addition to apo
structures, we successfully co-crystallized VvDapB K159A mutant with NADH. Structural
analysis shows several changes in the hydrogen bonding network in comparison with the
native protein. Based on these results, it is expected that this mutation may cause changes
in the rate of the enzyme reaction.
In parallel with structural studies, Dr. Tomasz Borowski group (data not published)
did computational calculations to decipher the mechanism of DapB reaction. Their results
show that the active site lysine (Lys160, NgDapB numbering) and histidine (His157,
NgDapB numbering) play an important role in the enzyme reaction. We have successfully
expressed and purified these mutants. Further structural and biochemical studies on these
mutants will help in obtaining experimental proof for these computational calculations and
may help in understanding the mechanism of enzyme reaction. Another way to is to
generate a double Lys-His mutant and assess its effects on the enzyme reaction. Along with
these two residues, co-crystallizing other mutants with NADH, NADPH will be helpful in
understanding the cofactor preference exhibited by DapB enzymes. Structure studies of
these mutants in complex with cofactor and substrate may also resulting in trapping of
reaction intermediates as is observed in several other bacterial enzymes

103-105

. All the

mutants studied here are highly conserved among DapB enzymes. Hence, there is a good
chance that some of these mutants may stabilize the reaction intermediates.
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In summary, studies structural and biochemical studies on these DapB mutants will
help in understanding the cofactor preference exhibited by DapB’s and help in evaluating
the role of active site environment on enzyme reaction.
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3.8. TABLES
Table 3.1. Primers used for mutagenesis.
Primer Name
D75A_F
D75A_R
N125A_F
N125A_R
N125D_F
N125D_R
H157A_F
H157A_R
K160A_F
K160A_R
D162A_F
D162A_R
D76A_F
D76A_R
H133A_F
H133A_R
K136A_F
K136A_R
D138A_F
D138A_R
D74A_F
D74A_R
H155A_F
H155A_R
K159A_F
K159A_R
D161A_F
D161A_R

Primer Sequence
NgDapB mutants

5' GTTCTGATTGcCTTTACGCGTCCG 3'
5' ATCGCTTTGCGCCAGCAC 3'
5' ATTCGCCGCTgcTTTCAGCGTC 3'
5' ACGATGCCGGTCTTTTCT 3'
5'ATTCGCCGCTgATTTCAGCGT 3'
5' ACGATGCCGGTCTTTTCTG 3'
5' TGAGGGCCACgcCCGTCACAAAG 3'
5' ATGATCTCGATGTCATAACC 3'
5' CCACCGTCACgcAGTCGATGCAC 3'
5' TGGCCCTCAATGATCTCG 3'
5' CACAAAGTCGcTGCACCGTCC 3'
5' ACGGTGGTGGCCCTCAAT 3'
MtDapB mutants
5' GTTGTCATTGcCTTCACGCAC 3'
5' TTCGGTGTTACCATCGGT 3'
5' CGAGCTGCACgcCCCGCATAAAGC 3'
5' ATCACCTCTGCGCTGTCG 3'
5' CCACCCGCATgcAGCGGATGCG 3'
5' TGCAGCTCGATCACCTCTG 3'
5' CATAAAGCGGcTGCGCCGAGC 3'
5' CGGGTGGTGCAGCTCGAT 3'
VvDapB mutants
5' GTCATCATCGcCTTCACCGCTC 3'
5' ATCAAACTGATCGATTTGTTTTG 3'
5' CGTTGAGGCAGCCCACCGTCAC 3'
5' ATCTCGATGTCACAGTAATC 3'
5' CCACCGTCACGCAGTCGATGCG
5' TGTGCCTCAACGATCTCG 3'
5' ACAAAGTCGcTGCGCCGTCTG 3'
5' ACGGTGGTGTGCCTCAAC 3'
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Table 3.2. Data sets for DapB mutant structures
Resolution Space
Protein Ligand
Å
Group
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.

N125A

none

1.8

I222

N125D

none

2.35

I222

H157A

none

1.85

I222

D51A

none

2.7

P21212

K136A

none

2.2

P21212

H133A

none

2.5

P21212

D138A

none

2

P21212

D138A

none

2.8

C2221

K159A

NADH

2

I222

Unit cell
parameters
Crystallization Conditions
α, β, γ
a, b, c (Å)
(°)
NgDapB mutants
57.9, 72.8, 90, 90,
138.9
90
0.1 M Bis-Tris, pH 6.5, 2.0 M Ammonium sulfate
58.0, 72.2, 90, 90,
139.1
90
0.1 M HEPES, pH 7.5, 2.0 M Ammonium sulfate
57.8, 72.3, 90, 90,
138.8
90
0.1 M HEPES, pH 7.5, 2.0 M Ammonium sulfate
MtDapB mutants
60.8,
90, 90,
122.6, 80.3 90
0.8 M Succinic acid, pH7.0
60.6,
90, 90, 0.2 M Lithium sulfate, 0.1 M Bis-Tris,
122.4, 81.2 90
pH 5.5, 25% w/v PEG 3350
59.1,
90, 90, 1 M Sodium potassium tartarate,
121.8, 80.0 90
100 mM Ches, pH 9.5, 200 mM Lithium sulfate
60.5,
121.5,
90, 90,
80.92
90
0.2 M Sodium formate, 20% w/v PEG 3350
78.6,
124.0,
90, 90, 0.02 M Magnesium chloride, 0.1 M HEPES, pH 7.5, 30% v/v
133.4
90
PEG monoethyl ether 550
VvDapB mutants
62.3, 86.6, 90, 90, 2M Ammonium sulfate, 100 mM Caps/NaOH,
111.9
90
pH 10.5, 200 mM Lithium sulfate

Beamline

22ID
22ID
22ID

22ID
22ID
22ID

19BM

22ID

19BM

Table 3.3. Crystallizations conditions for DapB mutants co-crystallized with ligands

Protein

Ligand

Crystallization condition

NgDapB N125A

NADH

0.2 M Magnesium chloride hexahydrate, 0.1 M
Tris-HCl, pH 8.5, 25% w/v PEG 3350

NgDapB N125A

NADH, 2,6-PDC

0.2 M Sodium chloride, 0.1 M Bis-Tris, pH 5.5,
25% w/v PEG 3350

VvDapB D74A

NADH, 2,6-PDC

0.2 M Sodium chloride, 0.1 M Bis-Tris, pH 5.5,
25% w/v PEG 3350

VvDapB K159A

NADH, 2,6-PDC

0.1 M HEPES, pH 7.5, 1.4 M Sodium citrate
tribasic hydrate

MtDapB K136A

NADH, 2,6-PDC

0.1 M Tris-HCl, pH8.5, 0.3 M Magnesium formate
dihydrate
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3.9. FIGURES

Figure 3.1. Residues forming nucleotide binding motif in DapB. Sequence alignment
of residues forming nucleotide binding motif of DapBs that have their structures
determined is shown. The highly conserved glycine’s in the GXXGXXG motif are
highlighted in green. The residues that are suspected to play important role nucleotide
specificity are in red.
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Figure 3.2. Conserved motif in oligomerization domain. Alignment of conserved motif
in oligomerization/ substrate binding domain of DapBs that have their structures
determined is shown. Highly conserved are highlighted in green.
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Figure 3.3. Main chain interaction of DapB with NADPH. A] EcDapB (PDB ID:
1DIH) and B] MtDapB (PDB ID: 5TJZ). The numbers show distances in Å.
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Figure 3.4. Active site mutants for DapB. NgDapB monomer is colored in cyan. The
active site residues that were mutated are shown in green. The ligands are in white.
Corresponding residues in MtDapB and VvDapB are listed in the table.
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Figure 3.5. Superposition of native and mutant structures of NgDapB. Native NgDapB
(PDB ID: 6BDX) is in green. Mutant NgDapB (N125A) is in blue. The mutated residue
Asn125 is marked and shown in purple in the native structure.
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Figure 3.6. Superposition of cofactors for native and mutant VvDapB structures.
NADH in the active site bound to native VvDapB (PDB ID: 5TEM) is in green and lysine
mutant of VvDapB (K159A) is in blue.
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Figure 3.7. Cofactor binding site of native VvDapB (top) and lysine mutant of
VvDapB (K159A) (bottom). Binding site residues and NADH are shown in grey and
green respectively. Hydrogen bonds between NADH and amino acids are represented by
black dashed lines and the distances are in Å.
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CHAPTER 4
INTERACTIONS OF 4- HYDROXY-TETRAHYDRODIPICOLINATE
REDUCTASE WITH COFACTORS AND POTENTIAL INHIBITORS
4.1. INTRODUCTION
Structural studies of NgDapB with NADH, 2,6-PDC and 2,5-FDC are described in
Chapter 2 (Figure 2.5 and 2.6). This identified several active site residues like Glu36,
Arg14, Arg78, Lys160, Thr101, Phe126, His157 and Thr167 that form hydrogen bond
interactions with NADH and substrate analogs in the active site of the enzyme. Chapter 3
elucidated the effect of the active site lysine mutation on the changes in the hydrogen
binding network that positions NADH. In continuation with this structural analysis, the
interactions of another DapB homolog, namely MtDapB, with NADH are described in this
chapter.
In addition to structural analysis of DapB-ligand interaction, we also aimed to
evaluate the binding of cofactor and substrate analogs with DapB’s in solution. Previous
studies describing the interaction of DapB with cofactors in solution using Isothermal
Titration Calorimetry (ITC) reveal that each DapB homolog has a unique preference for
either NADH or NADPH. EcDapB has greater affinity for NADH compared to NADPH
49

. On the other hand, S. aureus DapB (MRSA) binds NADPH with higher affinity

51, 74

(Table 4.1). Along with ITC studies, enzyme kinetics carried out in presence of either of
the cofactors also has provided some indication for preference for cofactors. TmDapB
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shows a slower reaction rate with NADH as a cofactor in comparison to NADPH (KM
values in presence of NADH and NADPH are 2.5 ± 0.3 µM and 0.6 ± 0.1 µM respectively)
49

. Kinetic studies with MtDapB suggest that this enzyme shows modest selectivity for

NADH over NADPH

92

. In regards to binding of substrate analog 2,6-PDC to DapB in

solution, there is no information available in literature. This chapter describes the binding
of cofactors with NgDapB and MtDapB in solution using ITC. Our first report on binding
of NgDapB with 2,6-PDC is shown. Additionally, the effect of mutations in NgDapB on
NADH binding is also discussed.
The aim of this research is to not only highlight the potential of DapB as a drug
target but also identify potential novel inhibitors. Structural and biochemical studies
described were done to understand the dynamics of DapB function. These studies will be
helpful in designing and identifying new inhibitors for this enzyme. In terms of inhibitor
development for DapB, the substrate analog 2,6-PDC is the only compound that is a known
inhibitor of DapB. Some other potential inhibitors were identified previously as described
in Chapter 1. However, there are no further studies indicating binding of these compounds
to DapB or highlighting their inhibitory potential. In our efforts to identify new potential
inhibitory compounds, we used DSF to screen a library of small molecules. The results for
the same are described in this chapter.
4.2. STRUCTURAL STUDIES ON MtDapB IN COMPLEX WITH NADH
MtDapB protein was expressed and purified from E. coli BL-21 cells as described
in Chapter 3. Co-crystallization experiments were set up by premixing MtDapB (10
mg/mL) with NADH (5mM final concentration). Crystallization trials were set up in 96
well crystallization plates (Hampton Research, Aliso Viejo, CA) using commercially
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available Index (Hampton Research, Aliso Viejo, CA) and Wizard Classic (Rigaku
Reagents, Bainbridge Island, WA) screens. The drops were set up as described in Chapter
2. Well diffracting crystals were obtained from crystallization condition 0.2 M lithium
sulfate monohydrate, 0.1 M Tris, pH 8.5, 25% w/v PEG 3350. Data collection, processing
and refinement was done as described in Chapter 2. The final coordinate files along with
structure factors were deposited to the Protein Data Bank with accession code 5UGV.
The structure of MtDapB with bound NADH was solved at 2.25 Å resolution with
R and Rfree values of 0.165 and 0.200 respectively. The protein crystallized in P21212 space
groups with two molecules in the AU. In chain A the nicotinamide ring is not modelled
since no corresponding electron density is seen. The structure also shows one sulfate ion
and one polyethylene glycol molecule from the crystallization condition. Janowski et al.
106

solved another structure of MtDapB bound to NADH previously. This structure was

solved in C2 space group at 2.35 Å resolution with R and Rfree values of 0.181 and 0.238
respectively (PDB ID: 1YL7). Both the structures are very similar and superpose with rmsd
value of 0.8Å over 245 Cα atoms. In both structures, all protein chains have NADH bound.
The cofactor and protein interact by forming several hydrogen bonds (Figure 4.1). The
nicotinamide ring hydrogen bonds with Pro103 whereas Thr77 form hydrogen with the
ribose of nicotinamide. The phosphate moieties form hydrogen bonds with Gly10, Lys11
and Val12. Asp33 interacts the ribose of adenine. The adenine ring shows no hydrogen
bond interactions with main chain residues. Similar to other bacterial homologs, MtDapB
also undergoes a conformational change upon ligand binding (Figure 4.2). Conformational
changes between apo-MtDapB (PDB ID: 5TEK), NADH bound MtDapB (PDB ID:
5UGV), NADH, 2,6-PDC bound MtDapB (PDB ID: 5TJY) and NADPH, 2,6-PDC bound
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MtDapB (PDB ID: 5TJZ) was studied using DynDom server 96. Binding of NADH results
in a change of 7° leading to partial closure of structure. Binding of both NADH and 2,6PDC induces a change of 32° resulting in complete closure of the monomer. Binding of the
other cofactor NADPH and 2,6-PDC also results into a similar change. This change is
induced by bending of residues Asn104-Met113 and Arg214-Gly220.
4.3. EXPERIMENTAL SETUP FOR ISOTHERMAL TITRATION STUDIES
Binding of NgDapB with nucleotides (NADH and NADPH) and substrate analog
2,6-pyridine dicarboxylic acid (2,6-PDC) and potential inhibitors, MtDapB with NADH
and NgDapB mutants with NADH was studied using ITC. Binding of NgDapB with
nucleotides was studied using a VP-ITC Micro Calorimeter (MicroCal, Northampton, MA)
whereas all the other experiments were done using Afinity ITC (TA Instruments, New
Castle, DE). Purified enzymes was buffer exchanged into 25 mM HEPES, pH 7.5 using
gel filtration chromatography as described in Chapter 2. 2 mM nucleotide and 2,6-PDC
solutions were prepared in the same buffer. Prior to use, these solutions were degassed
under vacuum using gentle stirring. For all the experiments involving NgDapB and
nucleotides, the final protein concentration in the sample cell was 75 µM. 4 µL of 2 mM
ligand was injected in 9.6 s for 25 injections with a spacing of 200 s between injections.
The syringe was rotated at 310 rpm. Data analysis was done using ORIGIN software
(OriginLab, Northampton, MA). For all other experiments, 100 µM protein was used.in
the sample cell. Ligands were injected over 20 injections of 1.5-2 µL each with interval of
250 s and syringe rotation of 150 rpm was used for every run. Protein with N-terminal Histag cleaved was used in all experiments. His-tag was cleaved using the protocol described
by Booth et al.

99

. Briefly, protein was mixed with recombinant TEV protease with N-
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terminal His-tag and dialyzed overnight at 4°C. The non His-tagged protein was then
separated from TEV protease using Ni-NTA affinity column as described in Chapter 2.
The temperature was maintained at 25°C for all the experiments and the experiments were
done in triplicate 56.
4.4. INTERACTIONS OF DapB WITH COFACTORS
Nucleotide specificity of NgDapB was determined using isothermal titration
calorimetry. Data analysis revealed that NgDapB can bind both the cofactors but has slight
preference for NADH. The dissociation constants (Kd) were found to be 2.5 ± 0.5 µM and
4.8 ± 0.6 µM for NADH and NADPH respectively (Figure 4.3). On the other hand,
MtDapB binds NADH with a Kd of 3.6 ± 0.4 µM (Figure 4.4, Table 4.2). It has been
speculated that the acidic and basic residues that are present around 20 amino acids down
the conserved GXXGXXG motif play an important role in cofactor affinity and specificity
of DapB enzyme 58. In EcDapB, residues Glu38 and Arg39 are important for binding of
NADH and NADPH. Arg39 stabilizes the ribose phosphate of NADPH

59

. In NgDapB,

Glu36 is conserved but His37 is the counterpart for Arg39.Crystal structure of NgDapB
bound to NADH described in Chapter 2 shows that Glu36 indeed stabilizes the ribose of
adenine. However, the role of His37 in NADPH binding cannot be confirmed due to lack
of crystal structure. In addition to cofactors, binding of 2,6-PDC to NgDapB was also
studied using ITC. This is the first study that assesses thermodynamic characterization of
2,6-PDC to any bacterial DapB. The analysis revealed that 2,6-PDC binds NgDapB with a
Kd of 21 ± 0.7µM (Figure 4.8) 56. In addition to these experiments were done to characterize
binding of MtDapB with NADPH, VvDapB with NADH and NADPH (data not shown).

70

All the experiments show the proteins bind to the respective ligands under study. More
optimizations are essential to calculate various thermodynamic parameters.
ITC experiments were also set up to study binding of NgDapB mutants with
NADH. The thermodynamic parameters are listed in Table 4.2. NgDapB H157A and
NgDapB K160 A bind NADH with a Kd of 1.2 ± 0.2 µM and 2.2 ± 0.1 µM respectively.
NgDapB D162A bind NADH with a Kd of 7.3 µM. No errors are reported for this mutant
since this value was generated in one experiment. The experiment needs to be replicated in
triplicates. These values are very similar to that of the naïve enzyme. Based on the location
of the mutants (Figure 3.3), we do not expect changes in NADH or NADPH binding for
the NgDapB H157A mutant since this residue interacts with substrate analog only. In the
case of NgDapB K160A and D162A mutants, we expect to see changes in binding of
cofactors. Our results show that these mutations do not have a significant effect on NADH.
However, they may affect NADPH binding. ITC characterization of NADPH binding is
essential to confirm this.
DapB should bind NADH with one site per monomer 56. For all the experiments,
the raw data was fitted into model for independent sites. Even though number of sites was
expected to be one, variations are seen as reported in Table 4.2. The odd binding
stoichiometry that is observed is most likely related to the errors in measuring the protein
concentration. For all experiments, the amount of protein was estimated using absorbance
at 280 nm. The mg/mL concentration was then converted into molarity and these values
were used as inputs for the ITC data analysis software. Later on, it was revealed that the
concentration estimated by A280 nm differs by that estimated by Bradford assay. This
difference is about 6%. When this is accounted for estimation of molar concentration, the
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molarity values show an error of ± 15 µM. It was found that this change in molar
concentration significantly changes the stoichiometry even though it does not does not
affect the Kd.
4.5. SCREENING AND INTERACTIONS WITH POTENTIAL INHIBITORS
The first approach that was used to identify potential inhibitors for DapB was to
generate a library of compounds that are structurally similar to 2,6-PDC and to analyze the
interaction of these compounds by structural studies and ITC analysis. The compounds that
were selected for this purpose are shown in Figure 4.7. In a second approach, a random
library of over 400 compounds was made. The effect of stability on NgDapB in presence
of these compounds was studied using DSF. cutNgDapB stored in 10 mM Tris, 150 mM
NaCl, pH 7.5 was used at 2 mg/mL concentration. SYPRO® Orange Dye (ThermoFisher,
Waltham, MA) was diluted 1:1000 in 1.0 mL of 2 mg/mL protein. This solution was mixed
with each compound in 1:1 ratio for a 20 µL total reaction volume in a Bio-Rad Hardshell
96-well RT-PCR plate (Hercules, CA). The plate was sealed using Microseal PCR Plate
Sealing Film (Bio-Rad, Hercules, CA). All experiments were performed in triplicates. An
experimental protocol to increase the temperature of the 96 well plate from 30-90°C in 2°C
increments after one minute intervals was used. Bio-Rad CFX Manager software was used
to determine the inflection point of melting curves (Tm). The results are shown in Figure
4.6. Compounds like 6-(ethoxycarbonyl) picolinic acid, 2,6-PDC, 3,4-hydroxybenzoic acid
and 3-hydroxy-2-naphthoic acid increased the Tm of NgDapB. 2,6-PDC which is a known
inhibitor of the enzyme increased the Tm by 6°C. The compounds mentioned above
increased the Tm by several degrees more than 2,6-PDC. Moreover, these compounds are
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structurally similar to 2,6-PDC. Hence, these are good candidates to study for inhibitory
potential.
Crystallization trails were set up to study the interactions of the compounds
identified in the study above with DapB homologs structurally. Several crystals were
grown (Table 4.3). However, they were of poor diffraction quality. Optimization studies
are underway. ITC experiments were also performed to study the binding of new potential
inhibitors; 2,5-FDC, 3,5-PDC and chelidamic acid. Results indicates that chelidamic acid
bind to NgDapB. (data not shown). In addition to ITC binding of chelidamic acid with
NgDapB was also evaluated with MicroScale thermophoresis technology (MST) 107 using
Monolith NT.115 (Nano Temper, Munich Germany) instrument. In this method either the
protein or the ligand under study are covalently attached to a fluorescent dye. The protein
is mixed with different concentrations of the ligand and transferred into capillaries.
Thermophoresis is then induced and detected in each capillary. Changes in thermophoresis
of the fluorescent molecules due to ligand binding are monitored 108. In case of NgDapB
chelidamic acid binding experiment, NgDapB was fluorescently labeled. The experimental
data generated confirmed that chelidamic acid binds to NgDapB (data not shown).
However, both ITC and MST experiments need optimization to calculate the binding
parameters.
4.6. DISCUSSION
The research presented here is directed towards understanding the mechanism of
DapB reaction and to identify inhibitors for these group of enzymes. One of the important
factors in inhibitor design is the thermodynamic profile of enzyme reaction 109. In general,
all thermodynamically favorable reactions exhibit negative free energy (ΔG < 0), but the
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changes in enthalpy and entropy are the actual driving factors that control the formation
and stability of protein-ligand complexes 110. Most protein-ligand binding reactions exhibit
the phenomenon of enthalpy-entropy compensation

111

. These enthalpic or entropic

contributions are often optimized to improve the binding affinity of potential inhibitors 110.
In case of DapB enzymes, little is known about the thermodynamic profile of the reaction
itself. Hence, our studies are directed towards characterizing these thermodynamic profiles.
Here we have used ITC to study the thermodynamic profiles of DapB enzymes with
cofactors and substrate analogs in solution.
The thermodynamic interactions of NgDapB with both the cofactors (NADH and
NADPH) and MtDapB and NgDapB mutants (H157A, K160A, D162A) with NADH were
studied. As expected, in all the experiments the energy change due to binding is exothermic
and energetically favorable for formation of non-covalent interactions between the proteins
and the cofactor. Binding of MtDapB to NADH is entropically unfavorable. This is
however compensated by a favorable enthalpy change resulting into an overall favorable
free energy change. On the other hand, binding of NgDapB to both its cofactors is favorable
in terms of enthalpy and entropy. A positive change in entropy is related to the changes in
solvation sphere. It is often an indication that water molecules have released from the active
site in process of binding
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. This observation is supported by the crystal structure of

NgDapB which shows presence of water molecules in the active site.
In addition to the binding of native NgDapB binding of NgDapB mutants (H157A,
K160A, D162A) with NADH was also studied using ITC. The results show that mutations
under study cause minimal changes in the overall free energy of binding (Table 4.1). The
change in enthalpy was found to be similar to that of the native protein. However, a major
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change was observed in the H157A mutant. This information may be useful in
understanding the mechanism of DapB reaction.
Earlier it was believed that DapB enzymes follow a ordered sequential mechanism
for their enzymatic reaction 58. The first step in the reaction is binding of cofactor that is
then followed by binding of the second substrate. Later, NMR based study published on
DapA and DapB enzymes indicated that the substrate can bind the enzyme in absence of
the cofactor

98

, which contradicted the previous belief. Apart from this NMR data there

was no other study available that supported this result. Our results on binding of NgDapB
with 2,6-PDC provide the first thermodynamic evidence that proves that DapB enzymes
can bind the substrate/substrate analog independently of the cofactor binding. It indicates
that these enzymes may follow random sequential mechanism rather than the ordered
sequential mechanism. This information is important for inhibitor design.
Current research on DapB inhibitor development has been described in Chapter 1.
These studies identify several compounds as potential inhibitors of DapB enzymes.
However, most of these studies are computational. Additionally, no experimental data is
available that evaluates the binding and inhibitory potential of these compounds to DapB
enzymes. 2,6-PDC is the only compound that has been previously shown to bind and inhibit
DapB enzymes 59, 92. Our studies have not only identified several new potential inhibitors
but have also shown binding of some of these compounds experimentally. We successfully
crystallized NgDapB in complex with NADH and a novel potential inhibitor, 2,5-FDC.
Additionally, we have also shown binding of chelidamic acid to NgDapB. Thus, this study
makes a valuable contribution towards inhibitor development for DapB enzymes.
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However, enzymatic studies are essential to characterize the inhibitory activity of these
compounds and to determine the mode of inhibition.
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4.7. TABLES
Table 4.1. Cofactor binding affinities for DapB’s. Dissociation constants (Kd) for NADH
or NADPH complexes with DapB’s from different bacteria determined by using Isothermal
Titration Calorimetry (ITC).
Organism

NADH (µM)

NADPH (µM)

Reference

E. coli

0.46 ± 0.04

2.1 ± 0.1

95

S. aureus

9.2 ± 0.2

0.9 ± 0.1

93

Methicillin resistant S. aureus

29 ± 2

1.5 ± 0.1

58

Paenisporosarcina sp.

No binding

37

52
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Table 4.2. Various thermodynamic parameters calculated for MtDapB and NgDapB
mutants using ITC data.

Kd (µM)

n

ΔH (kJ/mol)

ΔS (J/mol·K)

ΔG (kJ/mol)

NADH
MtDapB
NgDapB
H157A
NgDapB
K160A
NgDapB
D162A

3.6 ± 0.4

1.2 ± 0.2

-46.3 ± 2.5

-51.2

-31.0

1.2 ± 0.2

1.4 ± 0.01

-11.4 ± 1.1

75.0

-33.8

2.2 ± 0.1

1.2 ± 0.3

-13.5 ± 1.1

57.6

-30.5

7.3

1.1

-17.4

40.0

-29.3
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Table 4.3. Co-crystallization of DapB’s with potential inhibitors. Conditions from
which crystals for DapB co-crystallized with potential inhibitors were grown are shown.
Protein

Ligand

Crystallization condition

NgDapB

NADPH, 2,5FDC

NgDapB
VvDapB

2,5-FDC
2,6-PDC

VvDapB

2,5-FDC

0.1 M HEPES, pH 7.5, 2.0 M Ammonium
sulfate
0.1 M Bis-Tris, pH 5.5, 2.0 M Ammonium
sulfate
1.8 M Ammonium citrate tribasic, pH 7.0
0.1 M Bis-Tris, pH 5.5, 0.3 M Magnesium
formate dihydrate
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4.8. FIGURES

Figure 4.1. NADH binding site of MtDapB. Binding site residues and NADH are shown
in grey and green respectively. Hydrogen bonds between NADH and amino acids are
represented by black dashed lines. The distances shown are in Å.
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A] Apo and NADH bound MtDapB
PDB ID

5TEK
Chains

5TEK

A

5UGV
B:NADH

0

A

0

B
5UGV

A:NADH

B

A: NADH

6.8

6.2

0

B: NADH

7.1

5.1

5.8

0

B] Apo and NADH, 2,6-PDC bound MtDapB
PDB ID

5TEK
5TJY

Chains

A
B
A: NADH, 2,6-PDC

5TEK
A

0

5TJY
A: NADH, 2,6-PDC

B
0
33.9

31.9

0

C] Apo and NADPH, 2,6-PDC bound MtDapB
PDB ID
Chains

5TEK
5TJZ

A
B
A: NADPH, 2,6PDC

5TEK
A

5TJZ
A: NADPH, 2,6-PDC

B
0
0

32

34

0

Figure 4.2. Conformational changes in MtDapB structures. Apo and ligand bound
forms of MtDapB structures were compared. Conformational changes between different
chains in the structures were analyzed using DynDom server 96. The numbers indicate
change in the angle of rotation (°) between two chains. The chains that show significant
change in conformation are highlighted in green.
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Figure 4.3. Thermodynamic analysis of cofactor binding with NgDapB. Panel on the
left shows NADH binding profile and the right panel shows NADPH binding profile. The
top panels represent raw data.
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Figure 4.4. Thermodynamic analysis of NADH binding with MtDapB. The top panels
represent raw data.
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Figure 4.5. Thermodynamic analysis of substrate analog 2,6-PDC binding with
NgDapB. Top panel shows the raw data. The data fits to a model of independent binding
sites as calculated with Nano Analyze software (TA Instruments, New Castle, DE) 56.
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Temperature increase [⁰C]

14
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10
8
6
4
2
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Ligands

Figure 4.6. DSF results for ligand screening. X-axis shows the ligands that stabilize
NgDapB. Y-axis shows the difference between melting temperatures (Tm) in presence of
ligand and native protein (Tm for native protein 64ºC).
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Figure 4.7. Potential inhibitors for DapB enzymes. The compounds were selected
based on the structure similarity with 2,6-PDC.
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CHAPTER 5
SUMMARY CONCLUSIONS AND FUTURE DIRECTIONS
The work presented here focuses on biosynthesis of one amino acid, namely lysine.
The essentiality of this pathway in bacterial metabolism and the absence of homologous
counterparts in mammals make the enzymes from this pathway attractive drug targets 113.
This work aims to identify the potential of 4-hydroxy tetrahydrodipicolinate reductase
(DapB) from the lysine biosynthesis pathway as a drug target and to identify potential
inhibitory compounds for this enzyme. DapB enzyme has gained attention as a drug target
in the last decade. However, the availability of literature describing the structural and
functional aspects of this enzyme is limited. A fundamental understanding of enzyme
function is essential for development of inhibitors. This work uses structural and
biochemical approaches to understand the working of DapB. Enzymes from N.
gonorrhoeae (NgDapB), M. tuberculosis (MtDapB) and V. vulnificus (VvDapB) are
studied.
Chapter 1 describes different steps involved in lysine biosynthesis and the
importance of its products in bacterial metabolism. General structures and research directed
towards inhibitor development for ASADH and DapA is briefly discussed. The general
structure and domain organization of bacterial DapB is shown. A detailed cluster based
sequence analysis (CLANS) for over four thousand bacterial sequences within the domains
found in DapB enzymes is described. The results indicate that the analyzed sequences fall
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into four different (Figure 1.2) 4-hydroxy-tetrahydrodipicolinate reductase groups. Group
I is the largest cluster and comprises of DapB from Proteobacteria. The second group
consists of proteins from Bacteroidetes. Group III contains DapB’s from M. tuberculosis,
A. variabilis and C. glutamicum. Group IV on the other hand is composed of proteins
containing only the nucleotide binding domain from DapB. Along with CLANS analysis,
sequence identity matrix for DapB’s that have their structures determined in PDB is also
shown. These results indicate that all bacterial DapB’s share a high sequence identity. This
could be an added advantage since inhibitors for DapB from one bacterium may also inhibit
other DapB homologs. This highlights the potential of DapB as a target for broad-spectrum
antibiotic development.
Chapter 2 focuses on DapB from N. gonorrhoeae (NgDapB). This pathogen is the
leading cause of communicable diseases globally. Moreover, the pathogen exhibits very
high antibiotic resistance to the extent that it is speculated that these infections will soon
become untreatable. Expression, purification and crystallization of recombinant NgDapB
with N-terminal hexa-histidine tag is described. Stability studies on the His-NgDapB and
cutNgDapB are shown. These indicate that both the forms of proteins exhibit high thermal
stability (Tm of 76°C) and are stable in a pH range of 7.5-9.5 99. Furthermore, NgDapB was
crystallized successfully in apo and ligand bound forms. The apo structure of the enzyme
was solved at 1.85 Å resolution. The structural characterization and domain organization
of this enzyme is very similar to that of all the other bacterial homologs 56. NgDapB was
co-crystallized with cofactor NADH and the structure was determined at 1.4 Å.
Additionally, high resolution structures of NgDapB with substrate analog/ inhibitor and a
novel potential inhibitor, 2,5-FDC, were solved at 1.25 Å and 1.27 Å resolutions
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respectively. Analysis of these structures indicate that 2,5-FDC binds NgDapB in a manner
very similar to the known inhibitor 2,6-PDC, thus highlighting the inhibitory potential of
2,5-FDC.
Chapter 3 aims to identify important residues in the active site of DapB that have a
major effect on cofactor and substrate binding. DapB enzymes use NADH and NADPH as
cofactors. Literature shows that most DapBs can utilize both the cofactors but exhibit
preference for one cofactor. Structural and enzymatic studies have been done to identify
the reasoning behind this cofactor preference and some potentially important amino acids
have been identified. For instance, Arg39 in EcDapB, Lys9 and Lys11 in MtDapB and
His37 in PsDapB are suggested to be important. However, this data is insufficient to answer
the question of cofactor preference. This chapter describes mutation studies in MtDapB
and VvDapB along with NgDapB. Several active site residue mutants were generated using
site directed mutagenesis (Table 3.1). All the mutants were successfully expressed and
purified to high yields. Most of the mutants have been successfully crystallized in their apo
form. The apo structures, as expected, are very similar to the native enzymes. Additionally,
VvDapB K159A mutant was co-crystallized with NADH. Comparison of NADH binding
between native and mutant structures reveals several differences that may have
implications in cofactor preference. However, additional data is required to solve the
cofactor preference conundrum. Co-crystallization experiments with NADH and NADPH
can be performed to get crystal structures for remaining mutants. Additionally, the effect
of these mutations on binding of substrates and potential inhibitory molecules can be
studied.
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Chapter 4 describes the DSF method to identify potential inhibitory compounds for
DapB enzymes. 2,6-PDC which is a known substrate analog and inhibitor of DapB,
increases the stability of NgDapB in DSF assay. Hence, compounds that stabilize this
enzyme can also be studied for their inhibitory potential. A library of several hundred small
compounds was generated and the effect of these compounds on stability of NgDapB was
studied using DSF. Several compounds including 6-(ethoxycarbonyl) picolinic acids, 3hydroxy-2-napthoic acid, 3,4-hydroxybenzoic acid were identified as potential inhibitors.
Additionally, another small library of compounds was generated based on their structural
similarity to 2,6-PDC. The inhibitory potential of these compounds can be studied by cocrystallization with DapB. The binding of these compounds with DapB can also be
characterized by Isothermal Titration Calorimetry (ITC).
Apart from screening for inhibitors, this chapter also evaluates the thermodynamic
interactions of native and mutant NgDapB, VvDapB and MtDapB with cofactors and
substrate analog 2,6-PDC using ITC. The results show that NgDapB binds 2,6-PDC with
a Kd of 21 ±0.7 µM and exhibits slight preference for NADH over NADPH. Binding of
several NgDapB mutants (H157A, K160A and D162A) and native MtDapB with NADH
is discussed. More ITC experiments evaluating the effect of these mutations on NADPH
can be conducted. This might help in identification of active site residues that determine
the preference for cofactors.
In conclusion, based on the sequence analysis, this study identifies the potential of
4-hydroxy-tetrahydrodipicolinate reductase enzyme as a target for development of broadspectrum antibiotics. The first crystal structures of NgDapB in apo and ligand bound forms
are described. A high resolution structure of NgDapB bound to 2,5-FDC was determined
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at 1.27 Å resolution. This structure highlights the potential of 2,5-FDC as a novel inhibitor
for this enzyme. ITC studies with cofactors indicate that NgDapB and MtDapB might be
functionally similar to E. coli DapB. Additionally, this study identifies several other small
molecular compounds that may be potential inhibitors of DapB.
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